1
|
Nicol B, Vandenbossche-Goddard E, Thorpe C, Newman R, Patel H, Yates D. A workflow to practically apply true dose considerations to in vitro testing for next generation risk assessment. Toxicology 2024; 505:153826. [PMID: 38719068 DOI: 10.1016/j.tox.2024.153826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 04/22/2024] [Accepted: 05/01/2024] [Indexed: 05/14/2024]
Abstract
With the move away from safety testing assessment based on data generated in experimental animals the concept of Next Generation Risk Assessment (NGRA) has arisen which instead uses data from in silico and in vitro models. A key uncertainty in risk assessment is the actual dose of test chemical at the target site, and therefore surrogate dose metrics, such as nominal concentration in test media are used to describe in vitro effect (or no-effect) doses. The reliability and accuracy of the risk assessment therefore depends largely on our ability to understand and characterise the relationship between the dose metrics used and the actual biologically effective dose at the target site. The objective of this publication is to use 40 case study chemicals to illustrate how in vitro dose considerations can be applied to characterise the "true dose" and build confidence in the understanding of the biologically effective dose in in vitro test systems for the determination e.g. points of departure (PoDs) for NGRA. We propose a workflow that can be applied to assess whether the nominal test concentration can be considered a conservative dose metric for use in NGRA. The workflow examines the implications of volatility, stability, hydrophobicity, binding to plastic and serum, solubility, and the potential use of in silico models for some of these parameters. For the majority of the case study chemicals we found that the use of nominal concentrations in risk assessment would result in conservative decision making. However, for serval chemicals a potential for underestimation of the risk in humans in vivo based on in vitro nominal effect concentrations was identified, and approaches for refinement by characterisation of the actual effect concentration are proposed.
Collapse
Affiliation(s)
- Beate Nicol
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedford, Bedfordshire MK44 1LQ, UK
| | - Evita Vandenbossche-Goddard
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedford, Bedfordshire MK44 1LQ, UK.
| | - Charlotte Thorpe
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedford, Bedfordshire MK44 1LQ, UK
| | | | - Hiral Patel
- Charles River Laboratories, Cambridgeshire CB10 1XL, UK
| | - Dawn Yates
- Charles River Laboratories, Cambridgeshire CB10 1XL, UK
| |
Collapse
|
2
|
Jeon S, Lee EY, Nam SJ, Lim KM. Safety assessment of Paeonia lactiflora root extract for a cosmetic ingredient employing the threshold of toxicological concern (TTC) approach. Regul Toxicol Pharmacol 2024; 149:105620. [PMID: 38615840 DOI: 10.1016/j.yrtph.2024.105620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2023] [Revised: 03/29/2024] [Accepted: 04/03/2024] [Indexed: 04/16/2024]
Abstract
Botanical extracts, widely used in cosmetics, pose a challenge to safety assessment due to their complex compositions. The threshold of toxicological concern (TTC) approach, offering a safe exposure level for cosmetic ingredients, proves to be a promising solution for ensuring the safety of cosmetic ingredients with low exposure level. We assessed the safety of Paeonia lactiflora root extract (PLR), commonly used in skin conditioning products, with the TTC. We identified 50 constituents of PLR extract from the USDA database and literature exploration. Concentration of each constituent of PLR extract was determined with the information from USDA references, literature, and experimental analysis. The genotoxicity of PLR and its constituents was assessed in vitro and in silico respectively. Cramer class of the constituents of the PLR extract was determined with Toxtree 3.1 extended decision tree using ChemTunes®. Systemic exposure of each constituent from leave-on type cosmetic products containing PLR at a 1% concentration was estimated and compared with respective TTC threshold. Two constituents exceeding TTC threshold were further analyzed for dermal absorption using in silico tools, which confirmed the safety of PLR extract in cosmetics. Collectively, we demonstrated that the TTC is a useful tool for assessing botanical extract safety in cosmetics.
Collapse
Affiliation(s)
- Soha Jeon
- College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea
| | - Eun-Young Lee
- Department of Chemistry and Nanoscience, Ewha Womans University, Seoul, 03760, Republic of Korea
| | - Sang-Jip Nam
- Department of Chemistry and Nanoscience, Ewha Womans University, Seoul, 03760, Republic of Korea.
| | - Kyung-Min Lim
- College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea.
| |
Collapse
|
3
|
Sewell F, Alexander-White C, Brescia S, Currie RA, Roberts R, Roper C, Vickers C, Westmoreland C, Kimber I. New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption. Toxicol Res (Camb) 2024; 13:tfae044. [PMID: 38533179 PMCID: PMC10964841 DOI: 10.1093/toxres/tfae044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 02/07/2024] [Accepted: 03/07/2024] [Indexed: 03/28/2024] Open
Abstract
New approach methodologies (NAMs) can deliver improved chemical safety assessment through the provision of more protective and/or relevant models that have a reduced reliance on animals. Despite the widely acknowledged benefits offered by NAMs, there continue to be barriers that prevent or limit their application for decision-making in chemical safety assessment. These include barriers related to real and perceived scientific, technical, legislative and economic issues, as well as cultural and societal obstacles that may relate to inertia, familiarity, and comfort with established methods, and perceptions around regulatory expectations and acceptance. This article focuses on chemical safety science, exposure, hazard, and risk assessment, and explores the nature of these barriers and how they can be overcome to drive the wider exploitation and acceptance of NAMs. Short-, mid- and longer-term goals are outlined that embrace the opportunities provided by NAMs to deliver improved protection of human health and environmental security as part of a new paradigm that incorporates exposure science and a culture that promotes the use of protective toxicological risk assessments.
Collapse
Affiliation(s)
- Fiona Sewell
- UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London, NW1 2BE, United Kingdom
| | | | - Susy Brescia
- UK Chemicals Regulation Division, Health and Safety Executive, Redgrave Court, Bootle, Merseyside, L20 7HS, United Kingdom
| | - Richard A Currie
- Jealotts Hill International Research Centre, Syngenta, Bracknell, RG42 6EX, United Kingdom
| | - Ruth Roberts
- University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom
- ApconiX, BioHub at Alderley Park, Alderley Edge, SK10 4TG, United Kingdom
| | - Clive Roper
- Roper Toxicology Consulting Limited, 6 St Colme Street, Edinburgh, EH3 6AD, United Kingdom
| | - Catherine Vickers
- UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London, NW1 2BE, United Kingdom
| | - Carl Westmoreland
- Safety & Environmental Assurance Centre, Unilever, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Ian Kimber
- Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| |
Collapse
|
4
|
Silva AC, Loizou GD, McNally K, Osborne O, Potter C, Gott D, Colbourne JK, Viant MR. A novel method to derive a human safety limit for PFOA by gene expression profiling and modelling. FRONTIERS IN TOXICOLOGY 2024; 6:1368320. [PMID: 38577564 PMCID: PMC10991825 DOI: 10.3389/ftox.2024.1368320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 03/01/2024] [Indexed: 04/06/2024] Open
Abstract
Perfluorooctanoic acid (PFOA) is a persistent environmental contaminant that can accumulate in the human body due to its long half-life. This substance has been associated with liver, pancreatic, testicular and breast cancers, liver steatosis and endocrine disruption. PFOA is a member of a large group of substances also known as "forever chemicals" and the vast majority of substances of this group lack toxicological data that would enable their effective risk assessment in terms of human health hazards. This study aimed to derive a health-based guidance value for PFOA intake (ng/kg BW/day) from in vitro transcriptomics data. To this end, we developed an in silico workflow comprising five components: (i) sourcing in vitro hepatic transcriptomics concentration-response data; (ii) deriving molecular points of departure using BMDExpress3 and performing pathway analysis using gene set enrichment analysis (GSEA) to identify the most sensitive molecular pathways to PFOA exposure; (iii) estimating freely-dissolved PFOA concentrations in vitro using a mass balance model; (iv) estimating in vivo doses by reverse dosimetry using a PBK model for PFOA as part of a quantitative in vitro to in vivo extrapolation (QIVIVE) algorithm; and (v) calculating a tolerable daily intake (TDI) for PFOA. Fourteen percent of interrogated genes exhibited in vitro concentration-response relationships. GSEA pathway enrichment analysis revealed that "fatty acid metabolism" was the most sensitive pathway to PFOA exposure. In vitro free PFOA concentrations were calculated to be 2.9% of the nominal applied concentrations, and these free concentrations were input into the QIVIVE workflow. Exposure doses for a virtual population of 3,000 individuals were estimated, from which a TDI of 0.15 ng/kg BW/day for PFOA was calculated using the benchmark dose modelling software, PROAST. This TDI is comparable to previously published values of 1.16, 0.69, and 0.86 ng/kg BW/day by the European Food Safety Authority. In conclusion, this study demonstrates the combined utility of an "omics"-derived molecular point of departure and in silico QIVIVE workflow for setting health-based guidance values in anticipation of the acceptance of in vitro concentration-response molecular measurements in chemical risk assessment.
Collapse
Affiliation(s)
- Arthur de Carvalho e Silva
- School of Biosciences, University of Birmingham, Birmingham, United Kingdom
- Centre for Environmental Research and Justice (CERJ), University of Birmingham, Birmingham, United Kingdom
| | | | | | - Olivia Osborne
- Science Evidence and Research Division, Food Standards Agency, London, United Kingdom
| | - Claire Potter
- Science Evidence and Research Division, Food Standards Agency, London, United Kingdom
| | - David Gott
- Science Evidence and Research Division, Food Standards Agency, London, United Kingdom
| | - John K. Colbourne
- School of Biosciences, University of Birmingham, Birmingham, United Kingdom
- Centre for Environmental Research and Justice (CERJ), University of Birmingham, Birmingham, United Kingdom
| | - Mark R. Viant
- School of Biosciences, University of Birmingham, Birmingham, United Kingdom
- Centre for Environmental Research and Justice (CERJ), University of Birmingham, Birmingham, United Kingdom
| |
Collapse
|
5
|
Ebmeyer J, Najjar A, Lange D, Boettcher M, Voß S, Brandmair K, Meinhardt J, Kuehnl J, Hewitt NJ, Krueger CT, Schepky A. Next generation risk assessment: an ab initio case study to assess the systemic safety of the cosmetic ingredient, benzyl salicylate, after dermal exposure. Front Pharmacol 2024; 15:1345992. [PMID: 38515841 PMCID: PMC10955127 DOI: 10.3389/fphar.2024.1345992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 02/12/2024] [Indexed: 03/23/2024] Open
Abstract
We performed an ab initio next-generation risk assessment (NGRA) for a fragrance ingredient, benzyl salicylate (BSal), to demonstrate how cosmetic ingredients can be evaluated for systemic toxicity endpoints based on non-animal approaches. New approach methodologies (NAMs) used to predict the internal exposure included skin absorption assays, hepatocyte metabolism, and physiologically based pharmacokinetic (PBPK) modeling, and potential toxicodynamic effects were assessed using pharmacology profiling, ToxProfiler cell stress assay, transcriptomics in HepG2 and MCF-7 cells, ReproTracker developmental and reproductive toxicology (DART) assays, and cytotoxicity assays in human kidney cells. The outcome of the NGRA was compared to that of the traditional risk assessment approach based on animal data. The identification of the toxicologically critical entity was a critical step that directed the workflow and the selection of chemicals for PBPK modeling and testing in bioassays. The traditional risk assessment and NGRA identified salicylic acid (SA) as the "toxdriver." A deterministic PBPK model for a single-day application of 1.54 g face cream containing 0.5% BSal estimated the Cmax for BSal (1 nM) to be much lower than that of its major in vitro metabolite, SA (93.2 nM). Therefore, SA was tested using toxicodynamics bioassays. The lowest points of departure (PoDs) were obtained from the toxicogenomics assays. The interpretation of these results by two companies and methods were similar (SA only results in significant gene deregulation in HepG2 cells), but PoD differed (213 μM and 10.6 µM). A probabilistic PBPK model for repeated applications of the face cream estimated the highest Cmax of SA to be 630 nM. The resulting margins of internal exposure (MoIE) using the PoDs were 338 and 16, which were more conservative than those derived from external exposure and in vivo PoDs (margin of safety values were 9,705). In conclusion, both traditional and ab initio NGRA approaches concluded that the daily application of BSal in a cosmetic leave-on face cream at 0.5% is safe for humans. The processing and interpretation of toxicogenomics data can lead to different PoDs, which can subsequently affect the calculation of the MoIE. This case study supports the use of NAMs in a tiered NGRA ab initio approach.
Collapse
|
6
|
Ivan de Ávila R, Fentem J, Villela I, Somlo D, Fusco Almeida AM, Mendes-Giannini MJS, Di Pietro Micali Canavez A, Bosquetti B, Catarino CM, Schuck DC, Valadares BN, Facchini G, Marigliani B, Migliorini Figueira AC, Hickson R, Leme DM, Tagliati C, de Souza LCR, Maria Engler SS, Gaspar Cordeiro LR, Koepp J, Granjeiro JM, de Mello Brandao H, Munk M, Antunes de Mattos K, Pedralli B, Siqueira Furtuoso Rodrigues MM, Stival AC, Andrade J, Brito LB, Marques Dos Santos TR, Leite J, Garcia da Silva AC, Valadares MC. Brazilian National Network of Alternative Methods (RENAMA) 10th Anniversary: Meeting of the Associated Laboratories, May 2022. Altern Lab Anim 2024; 52:60-68. [PMID: 38061994 DOI: 10.1177/02611929231218378] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2024]
Abstract
The Brazilian National Network of Alternative Methods (RENAMA), which is linked to the Ministry of Science, Technology and Innovation, is currently comprised of 51 laboratories from CROs, academia, industry and government. RENAMA's aim is to develop and validate new approach methodologies (NAMs), as well as train researchers and disseminate information on their use - thus reducing Brazilian, and consequently Latin American, dependence on external technology. Moreover, it promotes the adoption of NAMs by educators and trained researchers, as well as the implementation of good laboratory practice (GLP) and the use of certified products. The RENAMA network started its activities in 2012, and was originally comprised of three central laboratories - the National Institute of Metrology, Quality and Technology (INMETRO); the National Institute of Quality Control in Health (INCQS); and the National Brazilian Biosciences Laboratory (LNBio) - and ten associated laboratories. In 2022, RENAMA celebrated its 10th anniversary, a milestone commemorated by the organisation of a meeting attended by different stakeholders, including the RENAMA-associated laboratories, academia, non-governmental organisations and industry. Ninety-six participants attended the meeting, held on 26 May 2022 in Balneário Camboriú, SC, Brazil, as part of the programme of the XXIII Brazilian Congress of Toxicology 2022. Significant moments of the RENAMA were remembered, and new goals and discussion themes were established. The lectures highlighted recent innovations in the toxicological sciences that have translated into the assessment of consumer product safety through the use of human-relevant NAMs instead of the use of existing animal-based approaches. The challenges and opportunities in accepting such practices for regulatory purposes were also presented and discussed.
Collapse
Affiliation(s)
- Renato Ivan de Ávila
- Unilever's Safety and Environmental Assurance Centre (SEAC), Colworth Science Park, Bedfordshire, UK
| | - Julia Fentem
- Unilever's Safety and Environmental Assurance Centre (SEAC), Colworth Science Park, Bedfordshire, UK
| | - Izabel Villela
- InnVitro Support and Management in Toxicology, Porto Alegre, Brazil
| | - Debora Somlo
- Unilever Brazil Industrial Ltda, WTorre Morumbi, São Paulo, Brazil
| | - Ana Marisa Fusco Almeida
- Laboratory of Proteomics and Clinical Mycology, Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, São Paulo State University, Araraquara, Brazil
| | - Maria José S Mendes-Giannini
- Laboratory of Proteomics and Clinical Mycology, Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, São Paulo State University, Araraquara, Brazil
| | | | - Bruna Bosquetti
- Safety Assessment Management, Grupo Boticário, Curitiba, Brazil
| | | | | | | | | | - Bianca Marigliani
- Research and Toxicology Department, Humane Society International (HSI), Rio de Janeiro, Brazil
| | | | | | | | - Carlos Tagliati
- Lab Tox, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | | | | | | | - Janice Koepp
- Biocelltis Biotechnology SA, Florianópolis, Brazil
| | - Jose Mauro Granjeiro
- National Institute of Metrology, Quality and Technology, Fluminense Federal University, Rio de Janeiro, Brazil
| | - Humberto de Mello Brandao
- Innovation Laboratory in Nanobiotechnology and Advanced Materials for Livestock Embrapa Gado de Leite, Juiz de Fora, Brazil
| | - Michele Munk
- Federal University of Juiz de Fora, Juiz de Fora, Brazil
| | - Katherine Antunes de Mattos
- Microbiological Control Laboratory, Quality Control Department, Bio-Manguinhos, Fiocruz, Rio de Janeiro, Brazil
| | - Bruna Pedralli
- Laboratory of Education and Research in In vitro Toxicology, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Brazil
| | | | - Ana Clara Stival
- Laboratory of Education and Research in In vitro Toxicology, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Brazil
| | - Jordana Andrade
- Laboratory of Education and Research in In vitro Toxicology, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Brazil
| | - Lara Barroso Brito
- Laboratory of Education and Research in In vitro Toxicology, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Brazil
| | - Thais Rosa Marques Dos Santos
- Laboratory of Education and Research in In vitro Toxicology, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Brazil
| | - Jacqueline Leite
- Laboratory of Education and Research in In vitro Toxicology, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Brazil
- Institute of Biological Sciences, Federal University of Goiás, Goiânia, Brazil
| | - Artur Christian Garcia da Silva
- Laboratory of Education and Research in In vitro Toxicology, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Brazil
| | - Marize Campos Valadares
- Laboratory of Education and Research in In vitro Toxicology, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Brazil
| |
Collapse
|
7
|
Cronin MTD, Ball N, Beken S, Bender H, Bercaru O, Caneva L, Corvaro M, Currie RA, Dawson JL, Desert P, Escher SE, Franco A, Irizar A, Mehta JM, Rogiers V, Tremblay RT, Westmoreland C, Maxwell G. Exposure considerations in human safety assessment: Report from an EPAA Partners' Forum. Regul Toxicol Pharmacol 2023; 144:105483. [PMID: 37640101 DOI: 10.1016/j.yrtph.2023.105483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 08/14/2023] [Accepted: 08/23/2023] [Indexed: 08/31/2023]
Abstract
Understanding and estimating the exposure to a substance is one of the fundamental requirements for safe manufacture and use. Many approaches are taken to determine exposure to substances, mainly driven by potential use and regulatory need. There are many opportunities to improve and optimise the use of exposure information for chemical safety. The European Partnership for Alternative Approaches to Animal Testing (EPAA) therefore convened a Partners' Forum (PF) to explore exposure considerations in human safety assessment of industrial products to agree key conclusions for the regulatory acceptance of exposure assessment approaches and priority areas for further research investment. The PF recognised the widescale use of exposure information across industrial sectors with the possibilities of creating synergies between different sectors. Further, the PF acknowledged that the EPAA could make a significant contribution to promote the use of exposure data in human safety assessment, with an aim to address specific regulatory needs. To achieve this, research needs, as well as synergies and areas for potential collaboration across sectors, were identified.
Collapse
Affiliation(s)
- Mark T D Cronin
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, United Kingdom.
| | - Nicholas Ball
- Dow Europe GmbH, Bachtobelstrasse, 8810, Horgen, Switzerland.
| | - Sonja Beken
- Federal Agency for Medicines and Health Products (FAMHP), Avenue Galilée 5/03, 1210, Brussels, Belgium.
| | | | - Ofelia Bercaru
- European Chemicals Agency, Telakkakatu 6, Helsinki, Finland.
| | - Laura Caneva
- Zoetis Belgium, Veterinary Medicine Research & Development, Mercuriusstraat 20, B-1930, Zaventem, Belgium.
| | | | - Richard A Currie
- Syngenta Jealott's Hill International Research Centre, Bracknell, RG42 6EY, UK.
| | - Jeffrey L Dawson
- United States Environmental Protection Agency, 1200 Pennsylvania Ave NW, Washington DC, 20004, USA.
| | - Paul Desert
- Sanofi, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
| | - Sylvia E Escher
- Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
| | - Antonio Franco
- European Commission, Joint Research Centre (JRC), Ispra, Italy.
| | - Amaia Irizar
- The International Fragrance Association (IFRA), Geneva, Switzerland.
| | | | - Vera Rogiers
- Faculty of Medicine and Pharmacy, In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090, Brussels, Belgium.
| | - Raphaël T Tremblay
- Procter & Gamble Services Company, Temselaan 100, 1853 Strombeek-Bever, Belgium.
| | - Carl Westmoreland
- Safety & Environmental Assurance Centre (SEAC), Unilever, Colworth Science Park, Sharnbrook, Bedford, MK44 1LQ, United Kingdom.
| | - Gavin Maxwell
- Safety & Environmental Assurance Centre (SEAC), Unilever, Colworth Science Park, Sharnbrook, Bedford, MK44 1LQ, United Kingdom.
| |
Collapse
|
8
|
Jeon S, Lee EY, Hillman PF, Nam SJ, Lim KM. Safety assessment of Cnidium officinale rhizome extract in cosmetics using the Threshold of Toxicological Concern (TTC) approach. Regul Toxicol Pharmacol 2023:105433. [PMID: 37302562 DOI: 10.1016/j.yrtph.2023.105433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 05/08/2023] [Accepted: 06/08/2023] [Indexed: 06/13/2023]
Abstract
Cosmetics often contain botanical extracts, which present a challenge for safety assessors due to their complex composition. The threshold of toxicological concern (TTC) approach is considered as a solution for the safety assessment of botanical extracts in cosmetics as part of next-generation risk assessment. In this study, we applied the TTC approach to evaluate the safety of Cnidium officinale rhizome extract (CORE), a widely used botanical extract in skin conditioning products. We identified 32 components of CORE through the USDA database and literature and determined the content of each component through literature or actual analysis where an authentic standard was available. Macro- and micronutrients were also analyzed to exclude them as safe components. The Toxtree® software was used to identify the Cramer class of remaining components. We estimated the systemic exposure of each component from leave-on type cosmetic products containing CORE at a 1% concentration and compared the results to TTC thresholds. All components of CORE had a systemic exposure below the TTC threshold. While batch variations and presence of unknown chemicals in individual CORE materials should be considered, this study demonstrated that the TTC approach can be a useful tool for the safety assessment of botanical extracts in cosmetics.
Collapse
Affiliation(s)
- Soha Jeon
- College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea
| | - Eun-Young Lee
- Department of Chemistry and Nanoscience, Ewha Womans University, Seoul, 03760, Republic of Korea
| | - Prima F Hillman
- Department of Chemistry and Nanoscience, Ewha Womans University, Seoul, 03760, Republic of Korea
| | - Sang-Jip Nam
- Department of Chemistry and Nanoscience, Ewha Womans University, Seoul, 03760, Republic of Korea.
| | - Kyung-Min Lim
- College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea.
| |
Collapse
|
9
|
Fentem JH. The 19th FRAME Annual Lecture, November 2022: Safer Chemicals and Sustainable Innovation Will Be Achieved by Regulatory Use of Modern Safety Science, Not by More Animal Testing. Altern Lab Anim 2023; 51:90-101. [PMID: 36856032 DOI: 10.1177/02611929231158236] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
The decisions we make on chemical safety, for consumers, workers and the environment, must be based on the best scientific data and knowledge available. Rapid advances in biology, in cell-based technologies and assays, and in analytical and computational approaches, have led to new types of highly relevant scientific data being generated. Such data enable us to improve the safety decisions we make, whilst also enabling us to avoid animal testing. Stimulated by the UK and EU bans on animal testing for cosmetics, Next Generation Risk Assessment (NGRA) approaches, which integrate various types of non-animal scientific data, have been established for assessing the safety of chemical ingredients used in cosmetics and other consumer products. In stark contrast, the chemicals regulations in Europe and other parts of the world have not kept pace with modern safety science and regulators are now mandating even more animal testing. Urgently closing this science-regulation gap is essential to upholding the EU's legislative requirement that any animal testing is a last resort. The ongoing revisions of UK and EU chemicals strategy and regulations provide an opportunity to fundamentally change the design and assessment paradigm needed to underpin safe and more sustainable innovation, through applying the best science and tools available rather than continuing to be anchored in animal tests dating back many decades. A range of initiatives have recently been launched in response to this urgent need, in the UK as well as in the EU.
Collapse
Affiliation(s)
- Julia H Fentem
- 3099Unilever Safety & Environmental Assurance Centre (SEAC), Bedford, UK
| |
Collapse
|
10
|
Magurany KA, Chang X, Clewell R, Coecke S, Haugabrooks E, Marty S. A Pragmatic Framework for the Application of New Approach Methodologies in One Health Toxicological Risk Assessment. Toxicol Sci 2023; 192:kfad012. [PMID: 36782355 PMCID: PMC10109535 DOI: 10.1093/toxsci/kfad012] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
Globally, industries and regulatory authorities are faced with an urgent need to assess the potential adverse effects of chemicals more efficiently by embracing new approach methodologies (NAMs). NAMs include cell and tissue methods (in vitro), structure-based/toxicokinetic models (in silico), methods that assess toxicant interactions with biological macromolecules (in chemico), and alternative models. Increasing knowledge on chemical toxicokinetics (what the body does with chemicals) and toxicodynamics (what the chemicals do with the body) obtained from in silico and in vitro systems continues to provide opportunities for modernizing chemical risk assessments. However, directly leveraging in vitro and in silico data for derivation of human health-based reference values has not received regulatory acceptance due to uncertainties in extrapolating NAM results to human populations, including metabolism, complex biological pathways, multiple exposures, interindividual susceptibility and vulnerable populations. The objective of this article is to provide a standardized pragmatic framework that applies integrated approaches with a focus on quantitative in vitro to in vivo extrapolation (QIVIVE) to extrapolate in vitro cellular exposures to human equivalent doses from which human reference values can be derived. The proposed framework intends to systematically account for the complexities in extrapolation and data interpretation to support sound human health safety decisions in diverse industrial sectors (food systems, cosmetics, industrial chemicals, pharmaceuticals etc.). Case studies of chemical entities, using new and existing data, are presented to demonstrate the utility of the proposed framework while highlighting potential sources of human population bias and uncertainty, and the importance of Good Method and Reporting Practices.
Collapse
Affiliation(s)
| | | | - Rebecca Clewell
- 21st Century Tox Consulting, Chapel Hill, North Carolina 27517, USA
| | - Sandra Coecke
- European Commission Joint Research Centre, Ispra, Italy
| | - Esther Haugabrooks
- Coca-Cola Company (formerly Physicians Committee for Responsible Medicine), Atlanta, Georgia 30313, USA
| | - Sue Marty
- The Dow Chemical Company, Midland, Michigan 48667, USA
| |
Collapse
|
11
|
Brescia S, Alexander-White C, Li H, Cayley A. Risk assessment in the 21st century: where are we heading? Toxicol Res (Camb) 2023; 12:1-11. [PMID: 36866215 PMCID: PMC9972812 DOI: 10.1093/toxres/tfac087] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 12/19/2022] [Accepted: 12/22/2022] [Indexed: 01/12/2023] Open
Abstract
Reliance on animal tests for chemical safety assessment is increasingly being challenged, not only because of ethical reasons, but also because they procrastinate regulatory decisions and because of concerns over the transferability of results to humans. New approach methodologies (NAMs) need to be fit for purpose and new thinking is required to reconsider chemical legislation, validation of NAMs and opportunities to move away from animal tests. This article summarizes the presentations from a symposium at the 2022 Annual Congress of the British Toxicology Society on the topic of the future of chemical risk assessment in the 21st century. The symposium included three case-studies where NAMs have been used in safety assessments. The first case illustrated how read-across augmented with some in vitro tests could be used reliably to perform the risk assessment of analogues lacking data. The second case showed how specific bioactivity assays could identify an NAM point of departure (PoD) and how this could be translated through physiologically based kinetic modelling in an in vivo PoD for the risk assessment. The third case showed how adverse-outcome pathway (AOP) information, including molecular-initiating event and key events with their underlying data, established for certain chemicals could be used to produce an in silico model that is able to associate chemical features of an unstudied substance with specific AOPs or AOP networks. The manuscript presents the discussions that took place regarding the limitations and benefits of these new approaches, and what are the barriers and the opportunities for their increased use in regulatory decision making.
Collapse
Affiliation(s)
- Susy Brescia
- Health & Safety Executive, Chemicals Regulation Division, Redgrave Court, Merton Road, Bootle, Merseyside L20 7HS, UK
| | | | - Hequn Li
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Alex Cayley
- Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds LS11, 5PS, UK
| |
Collapse
|
12
|
Chunduri V, Maddi S. Role of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: a comprehensive review. ADMET & DMPK 2022; 11:1-32. [PMID: 36778905 PMCID: PMC9909725 DOI: 10.5599/admet.1513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/10/2022] [Revised: 10/07/2022] [Indexed: 11/18/2022]
Abstract
Drug discovery and development have become a very time-consuming and expensive process. Preclinical animal models have become the gold standard for studying drug pharmacokinetic and toxicity parameters. However, the involvement of a huge number of animal subjects and inter-species pathophysiological variations between animals and humans has provoked a lot of debate, particularly because of ethical concerns. Although many efforts are being established by biotech and pharmaceutical companies for screening new chemical entities in vitro before preclinical trials, failures during clinical trials are still involved. Currently, a large number of two- dimensional (2D) in vitro assays have been developed and are being developed by researchers for the screening of compounds. Although these assays are helpful in screening a huge library of compounds and have shown perception, there is a significant lack in predicting human Absorption, Distribution, Metabolism, Excretion and Toxicology (ADME-Tox). As a result, these assays cannot completely replace animal models. The recent inventions in three-dimensional (3D) cell culture-based assays like organoids and micro-physiological systems have shown great potential alternative tools for predicting the compound pharmacokinetic and pharmacodynamic fate in humans. In this comprehensive review, we have summarized some of the most commonly used 2D in vitro assays and emphasized the achievements in next-generation 3D cell culture-based systems for predicting the compound ADME-Tox.
Collapse
|
13
|
Luijten M, Sprong RC, Rorije E, van der Ven LTM. Prioritization of chemicals in food for risk assessment by integrating exposure estimates and new approach methodologies: A next generation risk assessment case study. FRONTIERS IN TOXICOLOGY 2022; 4:933197. [PMID: 36199824 PMCID: PMC9527283 DOI: 10.3389/ftox.2022.933197] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Accepted: 08/02/2022] [Indexed: 11/15/2022] Open
Abstract
Next generation risk assessment is defined as a knowledge-driven system that allows for cost-efficient assessment of human health risk related to chemical exposure, without animal experimentation. One of the key features of next generation risk assessment is to facilitate prioritization of chemical substances that need a more extensive toxicological evaluation, in order to address the need to assess an increasing number of substances. In this case study focusing on chemicals in food, we explored how exposure data combined with the Threshold of Toxicological Concern (TTC) concept could be used to prioritize chemicals, both for existing substances and new substances entering the market. Using a database of existing chemicals relevant for dietary exposure we calculated exposure estimates, followed by application of the TTC concept to identify substances of higher concern. Subsequently, a selected set of these priority substances was screened for toxicological potential using high-throughput screening (HTS) approaches. Remarkably, this approach resulted in alerts for a selection of substances that are already on the market and represent relevant exposure in consumers. Taken together, the case study provides proof-of-principle for the approach taken to identify substances of concern, and this approach can therefore be considered a supportive element to a next generation risk assessment strategy.
Collapse
Affiliation(s)
- Mirjam Luijten
- Centre for Health Protection, Bilthoven, Netherlands
- *Correspondence: Mirjam Luijten,
| | - R. Corinne Sprong
- Centre for Nutrition, Prevention and Health Services, Bilthoven, Netherlands
| | - Emiel Rorije
- Centre for Safety of Substances and Products, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
| | | |
Collapse
|
14
|
Terasaka S, Hayashi A, Nukada Y, Yamane M. Investigating the uncertainty of prediction accuracy for the application of physiologically based pharmacokinetic models to animal-free risk assessment of cosmetic ingredients. Regul Toxicol Pharmacol 2022; 135:105262. [PMID: 36103952 DOI: 10.1016/j.yrtph.2022.105262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 08/17/2022] [Accepted: 09/07/2022] [Indexed: 11/17/2022]
Abstract
Physiologically based pharmacokinetic (PBPK) models are considered useful tools in animal-free risk assessment. To utilize PBPK models for risk assessment, it is necessary to compare their reliability with in vivo data. However, obtaining in vivo pharmacokinetics data for cosmetic ingredients is difficult, complicating the utilization of PBPK models for risk assessment. In this study, to utilize PBPK models for risk assessment without accuracy evaluation, we proposed a novel concept-the modeling uncertainty factor (MUF). By calculating the prediction accuracy for 150 compounds, we established that using in vitro data for metabolism-related parameters and limiting the applicability domain increase the prediction accuracy of a PBPK model. Based on the 97.5th percentile of prediction accuracy, MUF was defined at 10 for the area under the plasma concentration curve and 6 for Cmax. A case study on animal-free risk assessment was conducted for bisphenol A using these MUFs. As this study was conducted mainly on pharmaceuticals, further investigation using cosmetic ingredients is pivotal. However, since internal exposure is essential in realizing animal-free risk assessment, our concept will serve as a useful tool to predict plasma concentrations without using in vivo data.
Collapse
Affiliation(s)
- Shimpei Terasaka
- Kao Corporation, Safety Science Research, 2-1-3, Bunka, Sumida-Ku, Tokyo, 131-8501, Japan.
| | - Akane Hayashi
- Kao Corporation, Safety Science Research, 2-1-3, Bunka, Sumida-Ku, Tokyo, 131-8501, Japan
| | - Yuko Nukada
- Kao Corporation, Safety Science Research, 2-1-3, Bunka, Sumida-Ku, Tokyo, 131-8501, Japan
| | - Masayuki Yamane
- Kao Corporation, Safety Science Research, 2-1-3, Bunka, Sumida-Ku, Tokyo, 131-8501, Japan
| |
Collapse
|
15
|
Najjar A, Punt A, Wambaugh J, Paini A, Ellison C, Fragki S, Bianchi E, Zhang F, Westerhout J, Mueller D, Li H, Shi Q, Gant TW, Botham P, Bars R, Piersma A, van Ravenzwaay B, Kramer NI. Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment. Arch Toxicol 2022; 96:3407-3419. [PMID: 36063173 PMCID: PMC9584981 DOI: 10.1007/s00204-022-03356-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 08/03/2022] [Indexed: 11/28/2022]
Abstract
With an increasing need to incorporate new approach methodologies (NAMs) in chemical risk assessment and the concomitant need to phase out animal testing, the interpretation of in vitro assay readouts for quantitative hazard characterisation becomes more important. Physiologically based kinetic (PBK) models, which simulate the fate of chemicals in tissues of the body, play an essential role in extrapolating in vitro effect concentrations to in vivo bioequivalent exposures. As PBK-based testing approaches evolve, it will become essential to standardise PBK modelling approaches towards a consensus approach that can be used in quantitative in vitro-to-in vivo extrapolation (QIVIVE) studies for regulatory chemical risk assessment based on in vitro assays. Based on results of an ECETOC expert workshop, steps are recommended that can improve regulatory adoption: (1) define context and implementation, taking into consideration model complexity for building fit-for-purpose PBK models, (2) harmonise physiological input parameters and their distribution and define criteria for quality chemical-specific parameters, especially in the absence of in vivo data, (3) apply Good Modelling Practices (GMP) to achieve transparency and design a stepwise approach for PBK model development for risk assessors, (4) evaluate model predictions using alternatives to in vivo PK data including read-across approaches, (5) use case studies to facilitate discussions between modellers and regulators of chemical risk assessment. Proof-of-concepts of generic PBK modelling approaches are published in the scientific literature at an increasing rate. Working on the previously proposed steps is, therefore, needed to gain confidence in PBK modelling approaches for regulatory use.
Collapse
Affiliation(s)
| | - Ans Punt
- Wageningen Food Safety Research, Wageningen, The Netherlands
| | - John Wambaugh
- Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC USA
| | | | | | - Styliani Fragki
- National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | | | | | - Joost Westerhout
- The Netherlands Organisation for Applied Scientific Research TNO, Utrecht, The Netherlands
| | - Dennis Mueller
- Research and Development, Crop Science, Bayer AG, Monheim, Germany
| | - Hequn Li
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire UK
| | - Quan Shi
- Shell Global Solutions International B.V, The Hague, The Netherlands
| | - Timothy W. Gant
- School of Public Health, Faculty of Medicine, Imperial College London, London, UK
| | - Phil Botham
- Syngenta, Jealott’s Hill, Bracknell, Berkshire UK
| | - Rémi Bars
- Crop Science Division, Bayer S.A.S., Sophia Antipolis, France
| | - Aldert Piersma
- National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | | | - Nynke I. Kramer
- Toxicology Division, Wageningen University, PO Box 8000, 6700 EA Wageningen, The Netherlands
| |
Collapse
|
16
|
A State-of-the-Art Review on the Alternatives to Animal Testing for the Safety Assessment of Cosmetics. COSMETICS 2022. [DOI: 10.3390/cosmetics9050090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Almost a decade after the stipulated deadline in the 7th amendment to the EU Cosmetics Directive, which bans the marketing of animal-tested cosmetics in the EU from 2013, animal experimentation for cosmetic-related purposes remains a topic of animated debate. Cosmetic industry continues to be scrutinised for the practice, despite its leading role in funding and adopting innovation in this field. This paper aims to provide a state-of-the-art review of the field on alternative testing methods, also known as New Approach Methodologies (NAMs), with the focus on assessing the safety of cosmetic ingredients and products. It starts with innovation drivers and global regulatory responses, followed by an extensive, endpoint-specific overview of accepted/prospective NAMs. The overview covers main developments in acute toxicity, skin corrosion/irritation, serious eye damage/irritation, skin sensitisation, repeated dose toxicity, reproductive toxicity/endocrine disruption, mutagenicity/genotoxicity, carcinogenicity, photo-induced toxicity, and toxicokinetics. Specific attention was paid to the emerging in silico methodology. This paper also provides a brief overview of the studies on public perception of animal testing in cosmetics. It concludes with a view that educating consumers and inviting them to take part in advocacy could be an effective tool to achieve policy changes, regulatory acceptance, and investment in innovation.
Collapse
|
17
|
Khalidi H, Onasanwo A, Islam B, Jo H, Fisher C, Aidley R, Gardner I, Bois FY. SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp® simulator. Front Pharmacol 2022; 13:929200. [PMID: 36091744 PMCID: PMC9455594 DOI: 10.3389/fphar.2022.929200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Accepted: 07/01/2022] [Indexed: 11/24/2022] Open
Abstract
SimRFlow is a high-throughput physiologically based pharmacokinetic (PBPK) modelling tool which uses Certara’s Simcyp® simulator. The workflow is comprised of three main modules: 1) a Data Collection module for automated curation of physicochemical (from ChEMBL and the Norman Suspect List databases) and experimental data (i.e.: clearance, plasma-protein binding, and blood-to-plasma ratio, from httk-R package databases), 2) a Simulation module which activates the Simcyp® simulator and runs Monte Carlo simulations on virtual subjects using the curated data, and 3) a Data Visualisation module for understanding the simulated compound-specific profiles and predictions. SimRFlow has three administration routes (oral, intravenous, dermal) and allows users to change some simulation parameters including the number of subjects, simulation duration, and dosing. Users are only expected to provide a file of the compounds they wish to simulate, and in return the workflow provides summary statistics, concentration-time profiles of various tissue types, and a database file (containing in-depth results) for each simulated compound. This is presented within a guided and easy-to-use R Shiny interface which provides many plotting options for the visualisation of concentration-time profiles, parameter distributions, trends between the different parameters, as well as comparison of predicted parameters across all batch-simulated compounds. The in-built R functions can be assembled in user-customised scripts which allows for the modification of the workflow for different purposes. SimRFlow proves to be a time-efficient tool for simulating a large number of compounds without any manual curation of physicochemical or experimental data necessary to run Simcyp® simulations.
Collapse
|
18
|
Berggren E. Current trends in safety assessment of cosmetics ingredients. Regul Toxicol Pharmacol 2022; 134:105228. [PMID: 35863471 DOI: 10.1016/j.yrtph.2022.105228] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Elisabet Berggren
- European Commissionm, Joint Research Centre, Via E. Fermi 2749, I-21002, Ispra, VA, Italy.
| |
Collapse
|
19
|
Middleton AM, Reynolds J, Cable S, Baltazar MT, Li H, Beven S, Carmichael PL, Dent MP, Hatherell S, Houghton J, Kukic P, Liddell M, Malcomber S, Nicol B, Park B, Patel H, Scott S, Sparham C, Walker P, White A. Are non-animal systemic safety assessments protective? A toolbox and workflow. Toxicol Sci 2022; 189:124-147. [PMID: 35822611 PMCID: PMC9412174 DOI: 10.1093/toxsci/kfac068] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
An important question in toxicological risk assessment is whether non-animal new approach methodologies (NAMs) can be used to make safety decisions that are protective of human health, without being overly conservative. In this work, we propose a core NAM toolbox and workflow for conducting systemic safety assessments for adult consumers. We also present an approach for evaluating how protective and useful the toolbox and workflow are by benchmarking against historical safety decisions. The toolbox includes physiologically based kinetic (PBK) models to estimate systemic Cmax levels in humans, and 3 bioactivity platforms, comprising high-throughput transcriptomics, a cell stress panel, and in vitro pharmacological profiling, from which points of departure are estimated. A Bayesian model was developed to quantify the uncertainty in the Cmax estimates depending on how the PBK models were parameterized. The feasibility of the evaluation approach was tested using 24 exposure scenarios from 10 chemicals, some of which would be considered high risk from a consumer goods perspective (eg, drugs that are systemically bioactive) and some low risk (eg, existing food or cosmetic ingredients). Using novel protectiveness and utility metrics, it was shown that up to 69% (9/13) of the low risk scenarios could be identified as such using the toolbox, whilst being protective against all (5/5) the high-risk ones. The results demonstrated how robust safety decisions could be made without using animal data. This work will enable a full evaluation to assess how protective and useful the toolbox and workflow are across a broader range of chemical-exposure scenarios.
Collapse
Affiliation(s)
- Alistair M Middleton
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Joe Reynolds
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Sophie Cable
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Maria Teresa Baltazar
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Hequn Li
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Samantha Beven
- Discovery Services, Charles River, Chesterford Research Park, CB10 1XL, United Kingdom
| | - Paul L Carmichael
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Matthew Philip Dent
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Sarah Hatherell
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Jade Houghton
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Predrag Kukic
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Mark Liddell
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Sophie Malcomber
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Beate Nicol
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Benjamin Park
- Discovery Services, Charles River, Chesterford Research Park, CB10 1XL, United Kingdom
| | - Hiral Patel
- Cyprotex Discovery Ltd, No. 24 Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom
| | - Sharon Scott
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Chris Sparham
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Paul Walker
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| | - Andrew White
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, United Kingdom
| |
Collapse
|
20
|
Monte Carlo Models for Sub-Chronic Repeated-Dose Toxicity: Systemic and Organ-Specific Toxicity. Int J Mol Sci 2022; 23:ijms23126615. [PMID: 35743059 PMCID: PMC9224506 DOI: 10.3390/ijms23126615] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Revised: 06/09/2022] [Accepted: 06/10/2022] [Indexed: 12/04/2022] Open
Abstract
The risk-characterization of chemicals requires the determination of repeated-dose toxicity (RDT). This depends on two main outcomes: the no-observed-adverse-effect level (NOAEL) and the lowest-observed-adverse-effect level (LOAEL). These endpoints are fundamental requirements in several regulatory frameworks, such as the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) and the European Regulation of 1223/2009 on cosmetics. The RDT results for the safety evaluation of chemicals are undeniably important; however, the in vivo tests are time-consuming and very expensive. The in silico models can provide useful input to investigate sub-chronic RDT. Considering the complexity of these endpoints, involving variable experimental designs, this non-testing approach is challenging and attractive. Here, we built eight in silico models for the NOAEL and LOAEL predictions, focusing on systemic and organ-specific toxicity, looking into the effects on the liver, kidney and brain. Starting with the NOAEL and LOAEL data for oral sub-chronic toxicity in rats, retrieved from public databases, we developed and validated eight quantitative structure-activity relationship (QSAR) models based on the optimal descriptors calculated by the Monte Carlo method, using the CORAL software. The results obtained with these models represent a good achievement, to exploit them in a safety assessment, considering the importance of organ-related toxicity.
Collapse
|
21
|
Chang X, Tan YM, Allen DG, Bell S, Brown PC, Browning L, Ceger P, Gearhart J, Hakkinen PJ, Kabadi SV, Kleinstreuer NC, Lumen A, Matheson J, Paini A, Pangburn HA, Petersen EJ, Reinke EN, Ribeiro AJS, Sipes N, Sweeney LM, Wambaugh JF, Wange R, Wetmore BA, Mumtaz M. IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making. TOXICS 2022; 10:232. [PMID: 35622645 PMCID: PMC9143724 DOI: 10.3390/toxics10050232] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 04/24/2022] [Indexed: 02/04/2023]
Abstract
During the past few decades, the science of toxicology has been undergoing a transformation from observational to predictive science. New approach methodologies (NAMs), including in vitro assays, in silico models, read-across, and in vitro to in vivo extrapolation (IVIVE), are being developed to reduce, refine, or replace whole animal testing, encouraging the judicious use of time and resources. Some of these methods have advanced past the exploratory research stage and are beginning to gain acceptance for the risk assessment of chemicals. A review of the recent literature reveals a burst of IVIVE publications over the past decade. In this review, we propose operational definitions for IVIVE, present literature examples for several common toxicity endpoints, and highlight their implications in decision-making processes across various federal agencies, as well as international organizations, including those in the European Union (EU). The current challenges and future needs are also summarized for IVIVE. In addition to refining and reducing the number of animals in traditional toxicity testing protocols and being used for prioritizing chemical testing, the goal to use IVIVE to facilitate the replacement of animal models can be achieved through their continued evolution and development, including a strategic plan to qualify IVIVE methods for regulatory acceptance.
Collapse
Affiliation(s)
- Xiaoqing Chang
- Inotiv-RTP, 601 Keystone Park Drive, Suite 200, Morrisville, NC 27560, USA; (X.C.); (D.G.A.); (S.B.); (L.B.); (P.C.)
| | - Yu-Mei Tan
- U.S. Environmental Protection Agency, Office of Pesticide Programs, 109 T.W. Alexander Drive, Durham, NC 27709, USA;
| | - David G. Allen
- Inotiv-RTP, 601 Keystone Park Drive, Suite 200, Morrisville, NC 27560, USA; (X.C.); (D.G.A.); (S.B.); (L.B.); (P.C.)
| | - Shannon Bell
- Inotiv-RTP, 601 Keystone Park Drive, Suite 200, Morrisville, NC 27560, USA; (X.C.); (D.G.A.); (S.B.); (L.B.); (P.C.)
| | - Paul C. Brown
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20903, USA; (P.C.B.); (A.J.S.R.); (R.W.)
| | - Lauren Browning
- Inotiv-RTP, 601 Keystone Park Drive, Suite 200, Morrisville, NC 27560, USA; (X.C.); (D.G.A.); (S.B.); (L.B.); (P.C.)
| | - Patricia Ceger
- Inotiv-RTP, 601 Keystone Park Drive, Suite 200, Morrisville, NC 27560, USA; (X.C.); (D.G.A.); (S.B.); (L.B.); (P.C.)
| | - Jeffery Gearhart
- The Henry M. Jackson Foundation, Air Force Research Laboratory, 711 Human Performance Wing, Wright-Patterson Air Force Base, OH 45433, USA;
| | - Pertti J. Hakkinen
- National Library of Medicine, National Center for Biotechnology Information, 8600 Rockville Pike, Bethesda, MD 20894, USA;
| | - Shruti V. Kabadi
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Food Additive Safety, 5001 Campus Drive, HFS-275, College Park, MD 20740, USA;
| | - Nicole C. Kleinstreuer
- National Institute of Environmental Health Sciences, National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, P.O. Box 12233, Research Triangle Park, NC 27709, USA;
| | - Annie Lumen
- U.S. Food and Drug Administration, National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, USA;
| | - Joanna Matheson
- U.S. Consumer Product Safety Commission, Division of Toxicology and Risk Assessment, 5 Research Place, Rockville, MD 20850, USA;
| | - Alicia Paini
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy;
| | - Heather A. Pangburn
- Air Force Research Laboratory, 711 Human Performance Wing, 2729 R Street, Area B, Building 837, Wright-Patterson Air Force Base, OH 45433, USA;
| | - Elijah J. Petersen
- U.S. Department of Commerce, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD 20899, USA;
| | - Emily N. Reinke
- U.S. Army Public Health Center, 8252 Blackhawk Rd., Aberdeen Proving Ground, MD 21010, USA;
| | - Alexandre J. S. Ribeiro
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20903, USA; (P.C.B.); (A.J.S.R.); (R.W.)
| | - Nisha Sipes
- U.S. Environmental Protection Agency, Center for Computational Toxicology and Exposure, 109 TW Alexander Dr., Research Triangle Park, NC 27711, USA; (N.S.); (J.F.W.); (B.A.W.)
| | - Lisa M. Sweeney
- UES, Inc., 4401 Dayton-Xenia Road, Beavercreek, OH 45432, Assigned to Air Force Research Laboratory, 711 Human Performance Wing, Wright-Patterson Air Force Base, OH 45433, USA;
| | - John F. Wambaugh
- U.S. Environmental Protection Agency, Center for Computational Toxicology and Exposure, 109 TW Alexander Dr., Research Triangle Park, NC 27711, USA; (N.S.); (J.F.W.); (B.A.W.)
| | - Ronald Wange
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20903, USA; (P.C.B.); (A.J.S.R.); (R.W.)
| | - Barbara A. Wetmore
- U.S. Environmental Protection Agency, Center for Computational Toxicology and Exposure, 109 TW Alexander Dr., Research Triangle Park, NC 27711, USA; (N.S.); (J.F.W.); (B.A.W.)
| | - Moiz Mumtaz
- Agency for Toxic Substances and Disease Registry, Office of the Associate Director for Science, 1600 Clifton Road, S102-2, Atlanta, GA 30333, USA
| |
Collapse
|
22
|
Read-across and new approach methodologies applied in a 10-step framework for cosmetics safety assessment – A case study with parabens. Regul Toxicol Pharmacol 2022; 132:105161. [DOI: 10.1016/j.yrtph.2022.105161] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 01/23/2022] [Accepted: 03/17/2022] [Indexed: 11/17/2022]
|
23
|
Rajagopal R, Baltazar MT, Carmichael PL, Dent MP, Head J, Li H, Muller I, Reynolds J, Sadh K, Simpson W, Spriggs S, White A, Kukic P. Beyond AOPs: A Mechanistic Evaluation of NAMs in DART Testing. FRONTIERS IN TOXICOLOGY 2022; 4:838466. [PMID: 35295212 PMCID: PMC8915803 DOI: 10.3389/ftox.2022.838466] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 01/31/2022] [Indexed: 12/22/2022] Open
Abstract
New Approach Methodologies (NAMs) promise to offer a unique opportunity to enable human-relevant safety decisions to be made without the need for animal testing in the context of exposure-driven Next Generation Risk Assessment (NGRA). Protecting human health against the potential effects a chemical may have on embryo-foetal development and/or aspects of reproductive biology using NGRA is particularly challenging. These are not single endpoint or health effects and risk assessments have traditionally relied on data from Developmental and Reproductive Toxicity (DART) tests in animals. There are numerous Adverse Outcome Pathways (AOPs) that can lead to DART, which means defining and developing strict testing strategies for every AOP, to predict apical outcomes, is neither a tenable goal nor a necessity to ensure NAM-based safety assessments are fit-for-purpose. Instead, a pragmatic approach is needed that uses the available knowledge and data to ensure NAM-based exposure-led safety assessments are sufficiently protective. To this end, the mechanistic and biological coverage of existing NAMs for DART were assessed and gaps to be addressed were identified, allowing the development of an approach that relies on generating data relevant to the overall mechanisms involved in human reproduction and embryo-foetal development. Using the knowledge of cellular processes and signalling pathways underlying the key stages in reproduction and development, we have developed a broad outline of endpoints informative of DART. When the existing NAMs were compared against this outline to determine whether they provide comprehensive coverage when integrated in a framework, we found them to generally cover the reproductive and developmental processes underlying the traditionally evaluated apical endpoint studies. The application of this safety assessment framework is illustrated using an exposure-led case study.
Collapse
|
24
|
Bednarczyk E, Lu Y, Paini A, Batista Leite S, van Grunsven LA, Worth A, Whelan M. Extension of the Virtual Cell Based Assay from a 2-D to a 3-D Cell Culture Model. Altern Lab Anim 2022; 50:45-56. [PMID: 35238679 DOI: 10.1177/02611929221082200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Prediction of chemical toxicity is very useful in risk assessment. With the current paradigm shift towards the use of in vitro and in silico systems, we present herein a theoretical mathematical description of a quasi-diffusion process to predict chemical concentrations in 3-D spheroid cell cultures. By extending a 2-D Virtual Cell Based Assay (VCBA) model into a 3-D spheroid cell model, we assume that cells are arranged in a series of concentric layers within the sphere. We formulate the chemical quasi-diffusion process by simplifying the spheroid with respect to the number of cells in each layer. The system was calibrated and tested with acetaminophen (APAP). Simulated predictions of APAP toxicity were compared with empirical data from in vitro measurements by using a 3-D spheroid model. The results of this first attempt to extend the VCBA model are promising - they show that the VCBA model simulates close correlation between the influence of compound concentration and the viability of the HepaRG 3-D cell culture. The 3-D VCBA model provides a complement to current in vitro procedures to refine experimental setups, to fill data gaps and help in the interpretation of in vitro data for the purposes of risk assessment.
Collapse
Affiliation(s)
- Ewa Bednarczyk
- European Commission, 49566Joint Research Centre (JRC), Ispra, Italy
| | - Yanfei Lu
- European Commission, 49566Joint Research Centre (JRC), Ispra, Italy
| | - Alicia Paini
- European Commission, 49566Joint Research Centre (JRC), Ispra, Italy
| | | | - Leo A van Grunsven
- Liver Cell Biology Research Group, Vrije Universiteit Brussel, Brussel, Belgium
| | - Andrew Worth
- European Commission, 49566Joint Research Centre (JRC), Ispra, Italy
| | - Maurice Whelan
- European Commission, 49566Joint Research Centre (JRC), Ispra, Italy
| |
Collapse
|
25
|
Paini A, Campia I, Cronin MTD, Asturiol D, Ceriani L, Exner TE, Gao W, Gomes C, Kruisselbrink J, Martens M, Meek MEB, Pamies D, Pletz J, Scholz S, Schüttler A, Spînu N, Villeneuve DL, Wittwehr C, Worth A, Luijten M. Towards a qAOP framework for predictive toxicology - Linking data to decisions. COMPUTATIONAL TOXICOLOGY (AMSTERDAM, NETHERLANDS) 2022; 21:100195. [PMID: 35211660 PMCID: PMC8850654 DOI: 10.1016/j.comtox.2021.100195] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 07/23/2021] [Accepted: 10/09/2021] [Indexed: 12/22/2022]
Abstract
Chemical toxicity assessment depends on the quantification of kinetics and dynamics. Quantitative AOPs (qAOPs) are toxicodynamic models based on Adverse Outcome Pathways. Existing e-resources could form the basis of an e-infrastructure for qAOP modelling. Best practices for qAOP development, assessment and application are needed. Three qAOP case studies are presented to illustrate a modelling workflow.
The adverse outcome pathway (AOP) is a conceptual construct that facilitates organisation and interpretation of mechanistic data representing multiple biological levels and deriving from a range of methodological approaches including in silico, in vitro and in vivo assays. AOPs are playing an increasingly important role in the chemical safety assessment paradigm and quantification of AOPs is an important step towards a more reliable prediction of chemically induced adverse effects. Modelling methodologies require the identification, extraction and use of reliable data and information to support the inclusion of quantitative considerations in AOP development. An extensive and growing range of digital resources are available to support the modelling of quantitative AOPs, providing a wide range of information, but also requiring guidance for their practical application. A framework for qAOP development is proposed based on feedback from a group of experts and three qAOP case studies. The proposed framework provides a harmonised approach for both regulators and scientists working in this area.
Collapse
Affiliation(s)
- Alicia Paini
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Ivana Campia
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | | | - David Asturiol
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | | | - Thomas E Exner
- Edelweiss Connect GmbH, Technology Park Basel, Basel, Switzerland
| | - Wang Gao
- Institut National de l'Environnement Industriel et des Risques (INERIS), Verneuil-en-Halatte, France
| | | | | | | | | | - David Pamies
- Department of Physiology, Lausanne and Swiss Centre for Applied Human Toxicology (SCAHT), University of Lausanne, Lausanne, Switzerland
| | - Julia Pletz
- Liverpool John Moores University, Liverpool, United Kingdom
| | - Stefan Scholz
- Helmholtz Centre for Environmental Research GmbH - UFZ, Leipzig, Germany
| | - Andreas Schüttler
- Helmholtz Centre for Environmental Research GmbH - UFZ, Leipzig, Germany
| | - Nicoleta Spînu
- Liverpool John Moores University, Liverpool, United Kingdom
| | - Daniel L Villeneuve
- US Environmental Protection Agency, Great Lakes Toxicology and Ecology Division, Duluth, MN, USA
| | | | - Andrew Worth
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Mirjam Luijten
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| |
Collapse
|
26
|
Hewitt NJ, Troutman J, Przibilla J, Schepky A, Ouédraogo G, Mahony C, Kenna G, Varçin M, Dent MP. Use of in vitro metabolism and biokinetics assays to refine predicted in vivo and in vitro internal exposure to the cosmetic ingredient, phenoxyethanol, for use in risk assessment. Regul Toxicol Pharmacol 2022; 131:105132. [PMID: 35217105 DOI: 10.1016/j.yrtph.2022.105132] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 12/20/2021] [Accepted: 01/31/2022] [Indexed: 01/04/2023]
Abstract
A novel approach was developed to help characterize the biokinetics of the cosmetic ingredient, phenoxyethanol, to help assess the safety of the parent and its major stable metabolite. In the first step of this non-animal tiered approach, primary human hepatocytes were used to confirm or refute in silico predicted metabolites, and elucidate the intrinsic clearance of phenoxyethanol. A key result was the identification of the major metabolite, phenoxyacetic acid (PAA), the exposure to which in the kidney was subsequently predicted to far exceed that of phenoxyethanol in blood or other tissues. Therefore, a novel aspect of this approach was to measure in the subsequent step the formation of PAA in the cells dosed with phenoxyethanol that were used to provide points of departure (PoDs) and express the intracellular exposure as the Cmax and AUC24. This enabled the calculation of the intracellular concentrations of parent and metabolite at the PoD in the cells used to derive this value. These concentrations can be compared with in vivo tissue levels to conclude on the safety margin. The lessons from this case study will help to inform the design of other non-animal safety assessments.
Collapse
Affiliation(s)
- Nicola J Hewitt
- Cosmetics Europe, Avenue Herrmann-Debroux 40, 1160, Auderghem, Belgium
| | | | - Julia Przibilla
- Pharmacelsus GmbH, Science Park 2, D-66123, Saarbrücken, Germany
| | | | - Gladys Ouédraogo
- L'Oréal, Research & Innovation, 9 rue Pierre Dreyfus, 92110, Clichy, France
| | | | - Gerry Kenna
- Drug Safety Consultant, 2 Farmfield Drive, Macclesfield, Cheshire, SK10 2TJ, UK
| | - Mustafa Varçin
- Cosmetics Europe, Avenue Herrmann-Debroux 40, 1160, Auderghem, Belgium
| | - Mathew P Dent
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, UK
| |
Collapse
|
27
|
Loizou G, McNally K, Paini A, Hogg A. Derivation of a Human In Vivo Benchmark Dose for Bisphenol A from ToxCast In Vitro Concentration Response Data Using a Computational Workflow for Probabilistic Quantitative In Vitro to In Vivo Extrapolation. Front Pharmacol 2022; 12:754408. [PMID: 35222005 PMCID: PMC8874249 DOI: 10.3389/fphar.2021.754408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Accepted: 11/15/2021] [Indexed: 11/23/2022] Open
Abstract
A computational workflow which integrates physiologically based kinetic (PBK) modelling; global sensitivity analysis (GSA), Approximate Bayesian Computation (ABC), Markov Chain Monte Carlo (MCMC) simulation and the Virtual Cell Based Assay (VCBA) for the estimation of the active, free in vitro concentration of chemical in the reaction medium was developed to facilitate quantitative in vitro to in vivo extrapolation (QIVIVE). The workflow was designed to estimate parameter and model uncertainty within a computationally efficient framework. The workflow was tested using a human PBK model for bisphenol A (BPA) and high throughput screening (HTS) in vitro concentration-response data, for estrogen and pregnane X receptor activation determined in human liver and kidney cell lines, from the ToxCast/Tox21 database. In vivo benchmark dose 10% lower confidence limits (BMDL10) for oral uptake of BPA (ng/kg BW/day) were calculated from the in vivo dose-responses and compared to the human equivalent dose (HED) BMDL10 for relative kidney weight change in the mouse derived by European Food Safety Authority (EFSA). Three from four in vivo BMDL10 values calculated in this study were similar to the EFSA values whereas the fourth was much smaller. The derivation of an uncertainty factor (UF) to accommodate the uncertainties associated with measurements using human cell lines in vitro, extrapolated to in vivo, could be useful for the derivation of Health Based Guidance Values (HBGV).
Collapse
Affiliation(s)
- George Loizou
- Health and Safety Executive, Harpur Hill, Buxton, United Kingdom
- *Correspondence: George Loizou,
| | - Kevin McNally
- Health and Safety Executive, Harpur Hill, Buxton, United Kingdom
| | - Alicia Paini
- European Commission Joint Research Centre, Ispra, Italy
| | - Alex Hogg
- Health and Safety Executive, Harpur Hill, Buxton, United Kingdom
| |
Collapse
|
28
|
Implementing organ-on-chip in a next-generation risk assessment of chemicals: a review. Arch Toxicol 2022; 96:711-741. [PMID: 35103818 PMCID: PMC8850248 DOI: 10.1007/s00204-022-03234-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Accepted: 01/20/2022] [Indexed: 12/17/2022]
Abstract
Organ-on-chip (OoC) technology is full of engineering and biological challenges, but it has the potential to revolutionize the Next-Generation Risk Assessment of novel ingredients for consumer products and chemicals. A successful incorporation of OoC technology into the Next-Generation Risk Assessment toolbox depends on the robustness of the microfluidic devices and the organ tissue models used. Recent advances in standardized device manufacturing, organ tissue cultivation and growth protocols offer the ability to bridge the gaps towards the implementation of organ-on-chip technology. Next-Generation Risk Assessment is an exposure-led and hypothesis-driven tiered approach to risk assessment using detailed human exposure information and the application of appropriate new (non-animal) toxicological testing approaches. Organ-on-chip presents a promising in vitro approach by combining human cell culturing with dynamic microfluidics to improve physiological emulation. Here, we critically review commercial organ-on-chip devices, as well as recent tissue culture model studies of the skin, intestinal barrier and liver as the main metabolic organ to be used on-chip for Next-Generation Risk Assessment. Finally, microfluidically linked tissue combinations such as skin-liver and intestine-liver in organ-on-chip devices are reviewed as they form a relevant aspect for advancing toxicokinetic and toxicodynamic studies. We point to recent achievements and challenges to overcome, to advance non-animal, human-relevant safety studies.
Collapse
|
29
|
Alexander-White C, Bury D, Cronin M, Dent M, Hack E, Hewitt NJ, Kenna G, Naciff J, Ouedraogo G, Schepky A, Mahony C, Europe C. A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment. Regul Toxicol Pharmacol 2022; 129:105094. [PMID: 34990780 DOI: 10.1016/j.yrtph.2021.105094] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 07/12/2021] [Accepted: 12/02/2021] [Indexed: 02/07/2023]
Abstract
This paper presents a 10-step read-across (RAX) framework for use in cases where a threshold of toxicological concern (TTC) approach to cosmetics safety assessment is not possible. RAX builds on established approaches that have existed for more than two decades using chemical properties and in silico toxicology predictions, by further substantiating hypotheses on toxicological similarity of substances, and integrating new approach methodologies (NAM) in the biological and kinetic domains. NAM include new types of data on biological observations from, for example, in vitro assays, toxicogenomics, metabolomics, receptor binding screens and uses physiologically-based kinetic (PBK) modelling to inform about systemic exposure. NAM data can help to substantiate a mode/mechanism of action (MoA), and if similar chemicals can be shown to work by a similar MoA, a next generation risk assessment (NGRA) may be performed with acceptable confidence for a data-poor target substance with no or inadequate safety data, based on RAX approaches using data-rich analogue(s), and taking account of potency or kinetic/dynamic differences.
Collapse
Affiliation(s)
- Camilla Alexander-White
- MKTox & Co Ltd, 36 Fairford Crescent, Downhead Park, Milton Keynes, Buckinghamshire, MK15 9AQ, UK.
| | - Dagmar Bury
- L'Oreal Research & Innovation, 9 Rue Pierre Dreyfus, 92110, Clichy, France
| | - Mark Cronin
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 AF, UK
| | - Matthew Dent
- Unilever, Safety & Environmental Assurance Centre, Colworth House, Sharnbrook, Bedfordshire, MK44 1ET, UK
| | - Eric Hack
- ScitoVation, Research Triangle Park, Durham, NC, USA
| | - Nicola J Hewitt
- Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium
| | - Gerry Kenna
- Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium
| | - Jorge Naciff
- The Procter & Gamble Company, Cincinnati, OH, 45040, USA
| | - Gladys Ouedraogo
- L'Oreal Research & Innovation, 1 Avenue Eugène Schueller, Aulnay sous bois, France
| | | | | | - Cosmetics Europe
- Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium.
| |
Collapse
|
30
|
A hypothetical skin sensitisation next generation risk assessment for coumarin in cosmetic products. Regul Toxicol Pharmacol 2021; 127:105075. [PMID: 34728330 DOI: 10.1016/j.yrtph.2021.105075] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 10/04/2021] [Accepted: 10/27/2021] [Indexed: 11/21/2022]
Abstract
Next generation Risk Assessment (NGRA) is an exposure-led, hypothesis-driven approach which integrates new approach methodologies (NAMs) to assure safety without generating animal data. This hypothetical skin allergy risk assessment of two consumer products - face cream containing 0.1% coumarin and deodorant containing 1% coumarin - demonstrates the application of our skin allergy NGRA framework which incorporates our Skin Allergy Risk Assessment (SARA) Model. SARA uses Bayesian statistics to provide a human relevant point of departure and risk metric for a given chemical exposure based upon input data that can include both NAMs and historical in vivo studies. Regardless of whether NAM or in vivo inputs were used, the model predicted that the face cream and deodorant exposures were low and high risk respectively. Using only NAM data resulted in a minor underestimation of risk relative to in vivo. Coumarin is a predicted pro-hapten and consequently, when applying this mechanistic understanding to the selection of NAMs the discordance in relative risk could be minimized. This case study demonstrates how integrating a computational model and generating bespoke NAM data in a weight of evidence framework can build confidence in safety decision making.
Collapse
|
31
|
Macko P, Palosaari T, Whelan M. Extrapolating from acute to chronic toxicity in vitro. Toxicol In Vitro 2021; 76:105206. [PMID: 34186185 PMCID: PMC8434427 DOI: 10.1016/j.tiv.2021.105206] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 05/21/2021] [Accepted: 06/24/2021] [Indexed: 12/01/2022]
Abstract
Chemical safety assessment requires information on both chronic and acute effects of toxicants. Traditionally, such information has been provided by a set of animal studies conducted over different durations, ranging from a single dose with observation of effects over a few days, to repeat daily dosing and observations made over many months. With the advent of modern mechanistic approaches to toxicology, the role of in vitro studies within alternative approaches has never been more prominent. Typical in vitro experiments are conducted over short durations with measurements of response at a single time point, with a focus on providing effect and concentration-response information as input to hazard and risk assessment. This limits the usefulness of such data since potential chronic effects that cumulate over time are not usually considered. To address this, an experimental design is presented to characterise the toxicodynamics of a response not only in terms of concentration, but also as a function of time. Generation of concentration-time-effect responses allows both the extrapolation of points of departure from an acute to chronic exposure, and the determination of a chronicity index that provides a quantitative measure of a chemical's potential to cause cumulative effects over time. In addition, the approach provides a means to characterise the dynamics of key event relationships for the development of quantitative adverse outcome pathways.
Collapse
Affiliation(s)
- Peter Macko
- European Commission, Joint Research Centre (JRC), Ispra, Italy.
| | - Taina Palosaari
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Maurice Whelan
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| |
Collapse
|
32
|
Fentem J, Malcomber I, Maxwell G, Westmoreland C. Upholding the EU's Commitment to 'Animal Testing as a Last Resort' Under REACH Requires a Paradigm Shift in How We Assess Chemical Safety to Close the Gap Between Regulatory Testing and Modern Safety Science. Altern Lab Anim 2021; 49:122-132. [PMID: 34461762 DOI: 10.1177/02611929211040824] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Animal use for testing chemicals under REACH continues to increase, despite advances in non-animal safety science during the past 15 years. The application of modern science and technology, and the use of 'next generation' weight-of-evidence assessment approaches, are embedded in EU guidance for establishing the safety of cosmetics and foods - and of the ingredients used in these products. However, this is still not the case for the regulation of chemicals. Under the new Chemicals Strategy for Sustainability, thought leaders in human health and environmental protection are calling on the European Commission to quickly embrace the benefits of modern and innovative non-animal safety science, in place of outdated animal testing, if the EU is to be a leader in safe and sustainable innovation under the European Green Deal transformational change ambitions. The European Commission also needs to enable companies to meet their legal obligation to only conduct animal testing as a last resort, by providing a more flexible, science-based and consistent regulatory framework for assuring chemical safety, which supports the integration of data from different sources. We are at a tipping point for closing the gap between regulatory chemicals testing and modern safety science. It is time to join forces, across policy makers, scientists, regulators and lawyers, to lead the paradigm shift needed to deliver what EU citizens want - namely, chemicals and products that are safe and sustainable, without resorting to animal testing.
Collapse
Affiliation(s)
- Julia Fentem
- Unilever Safety & Environmental Assurance Centre (SEAC), 3099Unilever Plc, Bedfordshire, UK
| | - Ian Malcomber
- Unilever Safety & Environmental Assurance Centre (SEAC), 3099Unilever Plc, Bedfordshire, UK
| | - Gavin Maxwell
- Unilever Safety & Environmental Assurance Centre (SEAC), 3099Unilever Plc, Bedfordshire, UK
| | - Carl Westmoreland
- Unilever Safety & Environmental Assurance Centre (SEAC), 3099Unilever Plc, Bedfordshire, UK
| |
Collapse
|
33
|
Dent MP, Vaillancourt E, Thomas RS, Carmichael PL, Ouedraogo G, Kojima H, Barroso J, Ansell J, Barton-Maclaren TS, Bennekou SH, Boekelheide K, Ezendam J, Field J, Fitzpatrick S, Hatao M, Kreiling R, Lorencini M, Mahony C, Montemayor B, Mazaro-Costa R, Oliveira J, Rogiers V, Smegal D, Taalman R, Tokura Y, Verma R, Willett C, Yang C. Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients. Regul Toxicol Pharmacol 2021; 125:105026. [PMID: 34389358 PMCID: PMC8547713 DOI: 10.1016/j.yrtph.2021.105026] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 07/22/2021] [Accepted: 08/06/2021] [Indexed: 11/30/2022]
Abstract
Next generation risk assessment (NGRA) is an exposure-led, hypothesis-driven approach that has the potential to support animal-free safety decision-making. However, significant effort is needed to develop and test the in vitro and in silico (computational) approaches that underpin NGRA to enable confident application in a regulatory context. A workshop was held in Montreal in 2019 to discuss where effort needs to be focussed and to agree on the steps needed to ensure safety decisions made on cosmetic ingredients are robust and protective. Workshop participants explored whether NGRA for cosmetic ingredients can be protective of human health, and reviewed examples of NGRA for cosmetic ingredients. From the limited examples available, it is clear that NGRA is still in its infancy, and further case studies are needed to determine whether safety decisions are sufficiently protective and not overly conservative. Seven areas were identified to help progress application of NGRA, including further investments in case studies that elaborate on scenarios frequently encountered by industry and regulators, including those where a ‘high risk’ conclusion would be expected. These will provide confidence that the tools and approaches can reliably discern differing levels of risk. Furthermore, frameworks to guide performance and reporting should be developed.
Collapse
Affiliation(s)
- M P Dent
- Unilever Safety and Environmental Assurance Centre, Sharnbrook, Bedfordshire, MK44 1LQ, UK.
| | - E Vaillancourt
- Health Canada, Healthy Environments and Consumer Safety Branch, 269 Laurier Ave. W., Ottawa, ON K1A 0K9, Canada.
| | - R S Thomas
- Center for Computational Toxicology and Exposure, U.S. Environmental Protection Agency, Research, Triangle Park, NC, 27711, USA.
| | - P L Carmichael
- Unilever Safety and Environmental Assurance Centre, Sharnbrook, Bedfordshire, MK44 1LQ, UK.
| | - G Ouedraogo
- l'Oréal, Research and Development, Paris, France.
| | - H Kojima
- National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, 158-8501, Tokyo, Japan.
| | - J Barroso
- European Commission, Joint Research Centre (JRC), Ispra, VA, Italy.
| | - J Ansell
- US Personal Care Products Council (PCPC), 1620 L St. NW, Suite 1200, Washington, D.C, 20036, USA.
| | - T S Barton-Maclaren
- Health Canada, Healthy Environments and Consumer Safety Branch, 269 Laurier Ave. W., Ottawa, ON K1A 0K9, Canada.
| | - S H Bennekou
- National Food Institute, Technical University of Denmark (DTU), Copenhagen, Denmark.
| | - K Boekelheide
- Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
| | - J Ezendam
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
| | - J Field
- Health Canada, Healthy Environments and Consumer Safety Branch, 269 Laurier Ave. W., Ottawa, ON K1A 0K9, Canada.
| | - S Fitzpatrick
- US Food and Drug Administration (US FDA), Center for Food Safety and Applied Nutrition (CFSAN), 5001 Campus Drive, College Park, MD, 20740, USA.
| | - M Hatao
- Japan Cosmetic Industry Association (JCIA), Metro City Kamiyacho 6F, 5-1-5, Toranomon, Minato-ku, Tokyo, 105-0001 Japan.
| | - R Kreiling
- Clariant Produkte (Deutschland) GmbH, Am Unisyspark 1, 65843, Sulzbach, Germany.
| | - M Lorencini
- Grupo Boticário, Research & Development, São José dos Pinhais, Brazil.
| | - C Mahony
- Procter & Gamble Technical Centres Ltd, Reading, RG2 0RX, UK.
| | - B Montemayor
- Cosmetics Alliance Canada, 420 Britannia Road East Suite 102, Mississauga, ON L4Z 3L5, Canada.
| | - R Mazaro-Costa
- Departament of Pharmacology, Universidade Federal de Goiás, Goiânia, GO, 74.690-900, Brazil.
| | - J Oliveira
- Brazilian Health Regulatory Agency (ANVISA), Gerência de Produtos de Higiene, Perfumes, Cosméticos e Saneantes, Setor de Indústria e Abastecimento (SIA), Trecho 5, Área Especial 57, CEP 71205-050, Brasília, DF, Brazil.
| | - V Rogiers
- Vrije Universiteit Brussel, Brussels, Belgium.
| | - D Smegal
- US Food and Drug Administration (US FDA), Center for Food Safety and Applied Nutrition (CFSAN), 5001 Campus Drive, College Park, MD, 20740, USA.
| | - R Taalman
- Cosmetics Europe, Avenue Herrmann-Debroux 40, 1160 Auderghem, Belgium.
| | - Y Tokura
- Allergic Disease Research Center, Chutoen General Medical Center, Kakegawa, Japan.
| | - R Verma
- US Food and Drug Administration (US FDA), Center for Food Safety and Applied Nutrition (CFSAN), 5001 Campus Drive, College Park, MD, 20740, USA.
| | - C Willett
- Humane Society International, Washington, DC, USA.
| | - C Yang
- Taiwan Cosmetic Industry Association (TWCIA), 8F No. 136, Bo'ai Rd., Zhongzheng Dist., Taipei City, 100, Taiwan, ROC.
| |
Collapse
|
34
|
Arnesdotter E, Rogiers V, Vanhaecke T, Vinken M. An overview of current practices for regulatory risk assessment with lessons learnt from cosmetics in the European Union. Crit Rev Toxicol 2021; 51:395-417. [PMID: 34352182 DOI: 10.1080/10408444.2021.1931027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Risk assessments of various types of chemical compounds are carried out in the European Union (EU) foremost to comply with legislation and to support regulatory decision-making with respect to their safety. Historically, risk assessment has relied heavily on animal experiments. However, the EU is committed to reduce animal experimentation and has implemented several legislative changes, which have triggered a paradigm shift towards human-relevant animal-free testing in the field of toxicology, in particular for risk assessment. For some specific endpoints, such as skin corrosion and irritation, validated alternatives are available whilst for other endpoints, including repeated dose systemic toxicity, the use of animal data is still central to meet the information requirements stipulated in the different legislations. The present review aims to provide an overview of established and more recently introduced methods for hazard assessment and risk characterisation for human health, in particular in the context of the EU Cosmetics Regulation (EC No 1223/2009) as well as the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation (EC 1907/2006).
Collapse
Affiliation(s)
- Emma Arnesdotter
- Department of Pharmaceutical and Pharmacological Sciences, Research Group of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Brussels, Belgium
| | - Vera Rogiers
- Department of Pharmaceutical and Pharmacological Sciences, Research Group of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Brussels, Belgium
| | - Tamara Vanhaecke
- Department of Pharmaceutical and Pharmacological Sciences, Research Group of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Brussels, Belgium
| | - Mathieu Vinken
- Department of Pharmaceutical and Pharmacological Sciences, Research Group of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|
35
|
Loizou G, McNally K, Dorne JLCM, Hogg A. Derivation of a Human In Vivo Benchmark Dose for Perfluorooctanoic Acid From ToxCast In Vitro Concentration-Response Data Using a Computational Workflow for Probabilistic Quantitative In Vitro to In Vivo Extrapolation. Front Pharmacol 2021; 12:630457. [PMID: 34045957 PMCID: PMC8144460 DOI: 10.3389/fphar.2021.630457] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 03/01/2021] [Indexed: 01/11/2023] Open
Abstract
A computational workflow which integrates physiologically based kinetic (PBK) modeling, global sensitivity analysis (GSA), approximate Bayesian computation (ABC), and Markov Chain Monte Carlo (MCMC) simulation was developed to facilitate quantitative in vitro to in vivo extrapolation (QIVIVE). The workflow accounts for parameter and model uncertainty within a computationally efficient framework. The workflow was tested using a human PBK model for perfluorooctanoic acid (PFOA) and high throughput screening (HTS) in vitro concentration–response data, determined in a human liver cell line, from the ToxCast/Tox21 database. In vivo benchmark doses (BMDs) for PFOA intake (ng/kg BW/day) and drinking water exposure concentrations (µg/L) were calculated from the in vivo dose responses and compared to intake values derived by the European Food Safety Authority (EFSA). The intake benchmark dose lower confidence limit (BMDL5) of 0.82 was similar to 0.86 ng/kg BW/day for altered serum cholesterol levels derived by EFSA, whereas the intake BMDL5 of 6.88 was six-fold higher than the value of 1.14 ng/kg BW/day for altered antibody titer also derived by the EFSA. Application of a chemical-specific adjustment factor (CSAF) of 1.4, allowing for inter-individual variability in kinetics, based on biological half-life, gave an intake BMDL5 of 0.59 for serum cholesterol and 4.91 (ng/kg BW/day), for decreased antibody titer, which were 0.69 and 4.31 the EFSA-derived values, respectively. The corresponding BMDL5 for drinking water concentrations, for estrogen receptor binding activation associated with breast cancer, pregnane X receptor binding associated with altered serum cholesterol levels, thyroid hormone receptor α binding leading to thyroid disease, and decreased antibody titer (pro-inflammation from cytokines) were 0.883, 0.139, 0.086, and 0.295 ng/ml, respectively, with application of no uncertainty factors. These concentrations are 5.7-, 36-, 58.5-, and 16.9-fold lower than the median measured drinking water level for the general US population which is approximately, 5 ng/ml.
Collapse
Affiliation(s)
- George Loizou
- Health and Safety Executive, Harpur Hill, Buxton, United Kingdom
| | - Kevin McNally
- Health and Safety Executive, Harpur Hill, Buxton, United Kingdom
| | - Jean-Lou C M Dorne
- Scientific Committee and Emerging Risks Unit, European Food Safety Authority, Parma, Italy
| | - Alex Hogg
- Health and Safety Executive, Harpur Hill, Buxton, United Kingdom
| |
Collapse
|
36
|
Bury D, Alexander-White C, Clewell HJ, Cronin M, Desprez B, Detroyer A, Efremenko A, Firman J, Hack E, Hewitt NJ, Kenna G, Klaric M, Lester C, Mahony C, Ouedraogo G, Paini A, Schepky A. New framework for a non-animal approach adequately assures the safety of cosmetic ingredients - A case study on caffeine. Regul Toxicol Pharmacol 2021; 123:104931. [PMID: 33905778 DOI: 10.1016/j.yrtph.2021.104931] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 03/11/2021] [Accepted: 04/13/2021] [Indexed: 11/19/2022]
Abstract
This case study on the model substance caffeine demonstrates the viability of a 10-step read-across (RAX) framework in practice. New approach methodologies (NAM), including RAX and physiologically-based kinetic (PBK) modelling were used to assess the consumer safety of caffeine. Appropriate animal systemic toxicity data were used from the most relevant RAX analogue while assuming that no suitable animal toxicity data were available for caffeine. Based on structural similarities, three primary metabolites of the target chemical caffeine (theophylline, theobromine and paraxanthine) were selected as its most relevant analogues, to estimate a point of departure in order to support a next generation risk assessment (NGRA). On the basis of the pivotal mode of action (MOA) of caffeine and other methylxanthines, theophylline appeared to be the most potent and suitable analogue. A worst-case aggregate exposure assessment determined consumer exposure to caffeine from different sources, such as cosmetics and food/drinks. Using a PBK model to estimate human blood concentrations following exposure to caffeine, an acceptable Margin of Internal Exposure (MOIE) of 27-fold was derived on the basis of a RAX using theophylline animal data, which suggests that the NGRA approach for caffeine is sufficiently conservative to protect human health.
Collapse
Affiliation(s)
- Dagmar Bury
- L'Oréal, Research & Innovation, 9 Rue Pierre Dreyfus, 92110, Clichy, France.
| | - Camilla Alexander-White
- MKTox & Co Ltd, 36 Fairford Crescent, Downhead Park, Milton Keynes, Buckinghamshire, MK15 9AQ, UK
| | - Harvey J Clewell
- Ramboll Health Sciences, 3107 Armand Street, Monroe, LA, 71201, USA
| | - Mark Cronin
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 AF, UK
| | - Bertrand Desprez
- Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium
| | - Ann Detroyer
- L'Oréal, Research & Innovation, 1 Avenue Eugène Schueller, Aulnay-sous-Bois, France
| | | | - James Firman
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 AF, UK
| | - Eric Hack
- ScitoVation, Research Triangle Park, Durham, NC, USA
| | | | - Gerry Kenna
- Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium
| | - Martina Klaric
- Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium
| | | | | | - Gladys Ouedraogo
- L'Oréal, Research & Innovation, 1 Avenue Eugène Schueller, Aulnay-sous-Bois, France
| | - Alicia Paini
- European Commission Joint Research Centre, Ispra, Italy
| | | |
Collapse
|
37
|
Kühnl J, Tao TP, Brandmair K, Gerlach S, Rings T, Müller-Vieira U, Przibilla J, Genies C, Jaques-Jamin C, Schepky A, Marx U, Hewitt NJ, Maschmeyer I. Characterization of application scenario-dependent pharmacokinetics and pharmacodynamic properties of permethrin and hyperforin in a dynamic skin and liver multi-organ-chip model. Toxicology 2020; 448:152637. [PMID: 33220337 DOI: 10.1016/j.tox.2020.152637] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 11/11/2020] [Accepted: 11/12/2020] [Indexed: 12/12/2022]
Abstract
Microphysiological systems (MPS) aim to mimic the dynamic microenvironment and the interaction between tissues. While MPS exist for investigating pharmaceuticals, the applicability of MPS for cosmetics ingredients is yet to be evaluated. The HUMIMIC Chip2 ("Chip2″), is the first multi-organ chip technology to incorporate skin models, allowing for the topical route to be tested. Therefore, we have used this model to analyze the impact of different exposure scenarios on the pharmacokinetics and pharmacodynamics of two topically exposed chemicals, hyperforin and permethrin. The Chip2 incorporated reconstructed human epidermis models (EpiDerm™) and HepaRG-stellate spheroids. Initial experiments using static incubations of single organoids helped determine the optimal dose. In the Chip2 studies, parent and metabolites were analyzed in the circuit over 5 days after application of single and repeated topical or systemic doses. The gene expression of relevant xenobiotic metabolizing enzymes in liver spheroids was measured to reflect toxicodynamics effects of the compounds in liver. The results show that 1) metabolic capacities of EpiDerm™ and liver spheroids were maintained over five days; 2) EpiDerm™ model barrier function remained intact; 3) repeated application of compounds resulted in higher concentrations of parent chemicals and most metabolites compared to single application; 4) compound-specific gene induction e.g. induction of CYP3A4 by hyperforin depended on the application route and frequency; 5) different routes of application influenced the systemic concentrations of both parents and metabolites in the chip over the course of the experiment; 6) there was excellent intra- and inter-lab reproducibility. For permethrin, a process similar to the excretion in a human in vivo study could be simulated which was remarkably comparable to the in vivo situation. These results support the use of the Chip2 model to provide information on parent and metabolite disposition that may be relevant to risk assessment of topically applied cosmetics ingredients.
Collapse
Affiliation(s)
- Jochen Kühnl
- Beiersdorf AG, Unnastraße 48, D-20253, Hamburg, Germany.
| | - Thi Phuong Tao
- TissUse GmbH, Oudenarder Str. 16, D-13347, Berlin, Germany
| | | | - Silke Gerlach
- Beiersdorf AG, Unnastraße 48, D-20253, Hamburg, Germany
| | - Thamée Rings
- Beiersdorf AG, Unnastraße 48, D-20253, Hamburg, Germany
| | | | - Julia Przibilla
- Pharmacelsus GmbH, Science Park 2, D-66123, Saarbrücken, Germany
| | | | | | | | - Uwe Marx
- TissUse GmbH, Oudenarder Str. 16, D-13347, Berlin, Germany
| | - Nicola J Hewitt
- Cosmetics Europe, Avenue Herrmann-Debroux 40, 1160, Auderghem, Belgium
| | | |
Collapse
|
38
|
Madden JC, Enoch SJ, Paini A, Cronin MTD. A Review of In Silico Tools as Alternatives to Animal Testing: Principles, Resources and Applications. Altern Lab Anim 2020; 48:146-172. [PMID: 33119417 DOI: 10.1177/0261192920965977] [Citation(s) in RCA: 64] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Across the spectrum of industrial sectors, including pharmaceuticals, chemicals, personal care products, food additives and their associated regulatory agencies, there is a need to develop robust and reliable methods to reduce or replace animal testing. It is generally recognised that no single alternative method will be able to provide a one-to-one replacement for assays based on more complex toxicological endpoints. Hence, information from a combination of techniques is required. A greater understanding of the time and concentration-dependent mechanisms, underlying the interactions between chemicals and biological systems, and the sequence of events that can lead to apical effects, will help to move forward the science of reducing and replacing animal experiments. In silico modelling, in vitro assays, high-throughput screening, organ-on-a-chip technology, omics and mathematical biology, can provide complementary information to develop a complete picture of the potential response of an organism to a chemical stressor. Adverse outcome pathways (AOPs) and systems biology frameworks enable relevant information from diverse sources to be logically integrated. While individual researchers do not need to be experts across all disciplines, it is useful to have a fundamental understanding of what other areas of science have to offer, and how knowledge can be integrated with other disciplines. The purpose of this review is to provide those who are unfamiliar with predictive in silico tools, with a fundamental understanding of the underlying theory. Current applications, software, barriers to acceptance, new developments and the use of integrated approaches are all discussed, with additional resources being signposted for each of the topics.
Collapse
Affiliation(s)
- Judith C Madden
- School of Pharmacy and Biomolecular Sciences, 4589Liverpool John Moores University, Liverpool, UK
| | - Steven J Enoch
- School of Pharmacy and Biomolecular Sciences, 4589Liverpool John Moores University, Liverpool, UK
| | - Alicia Paini
- 99013European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Mark T D Cronin
- School of Pharmacy and Biomolecular Sciences, 4589Liverpool John Moores University, Liverpool, UK
| |
Collapse
|
39
|
Papadiamantis AG, Klaessig FC, Exner TE, Hofer S, Hofstaetter N, Himly M, Williams MA, Doganis P, Hoover MD, Afantitis A, Melagraki G, Nolan TS, Rumble J, Maier D, Lynch I. Metadata Stewardship in Nanosafety Research: Community-Driven Organisation of Metadata Schemas to Support FAIR Nanoscience Data. NANOMATERIALS (BASEL, SWITZERLAND) 2020; 10:E2033. [PMID: 33076428 PMCID: PMC7602672 DOI: 10.3390/nano10102033] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 10/08/2020] [Accepted: 10/11/2020] [Indexed: 12/15/2022]
Abstract
The emergence of nanoinformatics as a key component of nanotechnology and nanosafety assessment for the prediction of engineered nanomaterials (NMs) properties, interactions, and hazards, and for grouping and read-across to reduce reliance on animal testing, has put the spotlight firmly on the need for access to high-quality, curated datasets. To date, the focus has been around what constitutes data quality and completeness, on the development of minimum reporting standards, and on the FAIR (findable, accessible, interoperable, and reusable) data principles. However, moving from the theoretical realm to practical implementation requires human intervention, which will be facilitated by the definition of clear roles and responsibilities across the complete data lifecycle and a deeper appreciation of what metadata is, and how to capture and index it. Here, we demonstrate, using specific worked case studies, how to organise the nano-community efforts to define metadata schemas, by organising the data management cycle as a joint effort of all players (data creators, analysts, curators, managers, and customers) supervised by the newly defined role of data shepherd. We propose that once researchers understand their tasks and responsibilities, they will naturally apply the available tools. Two case studies are presented (modelling of particle agglomeration for dose metrics, and consensus for NM dissolution), along with a survey of the currently implemented metadata schema in existing nanosafety databases. We conclude by offering recommendations on the steps forward and the needed workflows for metadata capture to ensure FAIR nanosafety data.
Collapse
Affiliation(s)
- Anastasios G. Papadiamantis
- School of Geography, Earth and Environmental Sciences, University of Birmingham, Birmingham B15 2TT, UK
- Novamechanics Ltd., 1065 Nicosia, Cyprus; (A.A.); (G.M.)
| | | | | | - Sabine Hofer
- Department of Biosciences, Paris Lodron University of Salzburg, 5020 Salzburg, Austria; (S.H.); (N.H.); (M.H.)
| | - Norbert Hofstaetter
- Department of Biosciences, Paris Lodron University of Salzburg, 5020 Salzburg, Austria; (S.H.); (N.H.); (M.H.)
| | - Martin Himly
- Department of Biosciences, Paris Lodron University of Salzburg, 5020 Salzburg, Austria; (S.H.); (N.H.); (M.H.)
| | - Marc A. Williams
- U.S. Army Public Health Center (APHC), Aberdeen Proving Ground—South, Aberdeen, MD 21010, USA;
| | - Philip Doganis
- School of Chemical Engineering, National Technical University of Athens, 157 80 Athens, Greece;
| | | | | | | | - Tracy S. Nolan
- Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA;
| | - John Rumble
- R&R Data Services, Gaithersburg, MD 20877, USA;
- CODATA-VAMAS Working Group on Nanomaterials, 75016 Paris, France
| | | | - Iseult Lynch
- School of Geography, Earth and Environmental Sciences, University of Birmingham, Birmingham B15 2TT, UK
| |
Collapse
|
40
|
Gilmour N, Kern PS, Alépée N, Boislève F, Bury D, Clouet E, Hirota M, Hoffmann S, Kühnl J, Lalko JF, Mewes K, Miyazawa M, Nishida H, Osmani A, Petersohn D, Sekine S, van Vliet E, Klaric M. Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients. Regul Toxicol Pharmacol 2020; 116:104721. [DOI: 10.1016/j.yrtph.2020.104721] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 06/16/2020] [Accepted: 06/19/2020] [Indexed: 12/17/2022]
|
41
|
Gautier F, Tourneix F, Assaf Vandecasteele H, van Vliet E, Bury D, Alépée N. Read-across can increase confidence in the Next Generation Risk Assessment for skin sensitisation: A case study with resorcinol. Regul Toxicol Pharmacol 2020; 117:104755. [PMID: 32800849 DOI: 10.1016/j.yrtph.2020.104755] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 07/27/2020] [Accepted: 07/29/2020] [Indexed: 12/14/2022]
Abstract
Historically skin sensitisation risk assessment for cosmetic ingredients was based on animal models, however regulatory demands have led to Next Generation Risk Assessment (NGRA), using data from New Approach Methodologies (NAM) and Defined Approaches (DA). This case study was meant to investigate if the use of resorcinol at 0.2% in a face cream was safe and a maximum use concentration could be defined. The NAM data and DA predictions could not provide sufficient confidence to determine a point of departure (POD). Therefore, the application of read-across was explored to increase the level of confidence. Analogue searches in various tools and databases using "mode of action" and "chemical structural features" retrieved 535 analogues. After refinement by excluding analogues without a defined structure, similar reactivity profile and skin sensitisation data, 39 analogues remained. A final selection was made based on three approaches: expert judgment, chemical similarity or Local Lymph Node Assay data (LLNA). All read-across approaches supported a moderate potency. A POD derived from the LLNA EC3 of 3.6% was determined leading to a favourable NGRA conclusion and a maximum use concentration of 0.36%. This was supported by a traditional risk assessment based on the available animal data for resorcinol.
Collapse
Affiliation(s)
- Françoise Gautier
- L'Oréal, Research & Innovation, Aulnay-sous-Bois, France; L'Oréal, Research & Innovation, Clichy, France.
| | - Fleur Tourneix
- L'Oréal, Research & Innovation, Aulnay-sous-Bois, France; L'Oréal, Research & Innovation, Clichy, France.
| | - Hind Assaf Vandecasteele
- L'Oréal, Research & Innovation, Aulnay-sous-Bois, France; L'Oréal, Research & Innovation, Clichy, France.
| | - Erwin van Vliet
- Innovitox Consulting & Services, Regentenland 35, 3994TZ, Houten, the Netherlands.
| | - Dagmar Bury
- L'Oréal, Research & Innovation, Aulnay-sous-Bois, France; L'Oréal, Research & Innovation, Clichy, France.
| | - Nathalie Alépée
- L'Oréal, Research & Innovation, Aulnay-sous-Bois, France; L'Oréal, Research & Innovation, Clichy, France.
| |
Collapse
|
42
|
Baltazar MT, Cable S, Carmichael PL, Cubberley R, Cull T, Delagrange M, Dent MP, Hatherell S, Houghton J, Kukic P, Li H, Lee MY, Malcomber S, Middleton AM, Moxon TE, Nathanail AV, Nicol B, Pendlington R, Reynolds G, Reynolds J, White A, Westmoreland C. A Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products. Toxicol Sci 2020; 176:236-252. [PMID: 32275751 PMCID: PMC7357171 DOI: 10.1093/toxsci/kfaa048] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Next-Generation Risk Assessment is defined as an exposure-led, hypothesis-driven risk assessment approach that integrates new approach methodologies (NAMs) to assure safety without the use of animal testing. These principles were applied to a hypothetical safety assessment of 0.1% coumarin in face cream and body lotion. For the purpose of evaluating the use of NAMs, existing animal and human data on coumarin were excluded. Internal concentrations (plasma Cmax) were estimated using a physiologically based kinetic model for dermally applied coumarin. Systemic toxicity was assessed using a battery of in vitro NAMs to identify points of departure (PoDs) for a variety of biological effects such as receptor-mediated and immunomodulatory effects (Eurofins SafetyScreen44 and BioMap Diversity 8 Panel, respectively), and general bioactivity (ToxCast data, an in vitro cell stress panel and high-throughput transcriptomics). In addition, in silico alerts for genotoxicity were followed up with the ToxTracker tool. The PoDs from the in vitro assays were plotted against the calculated in vivo exposure to calculate a margin of safety with associated uncertainty. The predicted Cmax values for face cream and body lotion were lower than all PoDs with margin of safety higher than 100. Furthermore, coumarin was not genotoxic, did not bind to any of the 44 receptors tested and did not show any immunomodulatory effects at consumer-relevant exposures. In conclusion, this case study demonstrated the value of integrating exposure science, computational modeling and in vitro bioactivity data, to reach a safety decision without animal data.
Collapse
Affiliation(s)
- Maria T Baltazar
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Sophie Cable
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Paul L Carmichael
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Richard Cubberley
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Tom Cull
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Mona Delagrange
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Matthew P Dent
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Sarah Hatherell
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Jade Houghton
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Predrag Kukic
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Hequn Li
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Mi-Young Lee
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Sophie Malcomber
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Alistair M Middleton
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Thomas E Moxon
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Alexis V Nathanail
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Beate Nicol
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Ruth Pendlington
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Georgia Reynolds
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Joe Reynolds
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Andrew White
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| | - Carl Westmoreland
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
| |
Collapse
|
43
|
Tebby C, van der Voet H, de Sousa G, Rorije E, Kumar V, de Boer W, Kruisselbrink JW, Bois FY, Faniband M, Moretto A, Brochot C. A generic PBTK model implemented in the MCRA platform: Predictive performance and uses in risk assessment of chemicals. Food Chem Toxicol 2020; 142:111440. [PMID: 32473292 DOI: 10.1016/j.fct.2020.111440] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Revised: 05/07/2020] [Accepted: 05/15/2020] [Indexed: 12/13/2022]
Abstract
Physiologically-based toxicokinetic (PBTK) models are important tools for in vitro to in vivo or inter-species extrapolations in health risk assessment of foodborne and non-foodborne chemicals. Here we present a generic PBTK model implemented in the EuroMix toolbox, MCRA 9 and predict internal kinetics of nine chemicals (three endocrine disrupters, three liver steatosis inducers, and three developmental toxicants), in data-rich and data-poor conditions, when increasingly complex levels of parametrization are applied. At the first stage, only QSAR models were used to determine substance-specific parameters, then some parameter values were refined by estimates from substance-specific or high-throughput in vitro experiments. At the last stage, elimination or absorption parameters were calibrated based on available in vivo kinetic data. The results illustrate that parametrization plays a capital role in the output of the PBTK model, as it can change how chemicals are prioritized based on internal concentration factors. In data-poor situations, estimates can be far from observed values. In many cases of chronic exposure, the PBTK model can be summarized by an external to internal dose factor, and interspecies concentration factors can be used to perform interspecies extrapolation. We finally discuss the implementation and use of the model in the MCRA risk assessment platform.
Collapse
Affiliation(s)
- Cleo Tebby
- INERIS, Unit Models for Ecotoxicology and Toxicology (METO), Verneuil-en-Halatte, France.
| | | | | | - Emiel Rorije
- RIVM, Centre for Safety of Substances and Products, Department for Consumers and Product Safety, P.O. Box 1, 3720, BA Bilthoven, Netherlands
| | - Vikas Kumar
- URV, Universitat Rovira i Virgili, C/ Països Catalans, nº 26, 43007, Tarragona (Tarragona- Catalonia), Spain
| | - Waldo de Boer
- Wageningen University & Research, Biometris, Wageningen, Netherlands
| | | | - Frédéric Y Bois
- INERIS, Unit Models for Ecotoxicology and Toxicology (METO), Verneuil-en-Halatte, France
| | - Moosa Faniband
- Division of Occupational and Environmental Medicine, Faculty of Medicine, Lund University, Sweden
| | - Angelo Moretto
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Italy
| | - Céline Brochot
- INERIS, Unit Models for Ecotoxicology and Toxicology (METO), Verneuil-en-Halatte, France
| |
Collapse
|
44
|
Mahony C, Ashton RS, Birk B, Boobis AR, Cull T, Daston GP, Ewart L, Knudsen TB, Manou I, Maurer-Stroh S, Margiotta-Casaluci L, Müller BP, Nordlund P, Roberts RA, Steger-Hartmann T, Vandenbossche E, Viant MR, Vinken M, Whelan M, Zvonimir Z, Cronin MTD. New ideas for non-animal approaches to predict repeated-dose systemic toxicity: Report from an EPAA Blue Sky Workshop. Regul Toxicol Pharmacol 2020; 114:104668. [PMID: 32335207 DOI: 10.1016/j.yrtph.2020.104668] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 04/10/2020] [Accepted: 04/17/2020] [Indexed: 02/09/2023]
Abstract
The European Partnership for Alternative Approaches to Animal Testing (EPAA) convened a 'Blue Sky Workshop' on new ideas for non-animal approaches to predict repeated-dose systemic toxicity. The aim of the Workshop was to formulate strategic ideas to improve and increase the applicability, implementation and acceptance of modern non-animal methods to determine systemic toxicity. The Workshop concluded that good progress is being made to assess repeated dose toxicity without animals taking advantage of existing knowledge in toxicology, thresholds of toxicological concern, adverse outcome pathways and read-across workflows. These approaches can be supported by New Approach Methodologies (NAMs) utilising modern molecular technologies and computational methods. Recommendations from the Workshop were based around the needs for better chemical safety assessment: how to strengthen the evidence base for decision making; to develop, standardise and harmonise NAMs for human toxicity; and the improvement in the applicability and acceptance of novel techniques. "Disruptive thinking" is required to reconsider chemical legislation, validation of NAMs and the opportunities to move away from reliance on animal tests. Case study practices and data sharing, ensuring reproducibility of NAMs, were viewed as crucial to the improvement of non-animal test approaches for systemic toxicity.
Collapse
Affiliation(s)
| | - Randolph S Ashton
- Department of Biomedical Engineering & Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, 53715, USA.
| | - Barbara Birk
- BASF SE, Experimental Toxicology and Ecology, Carl-Bosch-Straβe 38, 67056, Ludwigshafen, Germany.
| | - Alan R Boobis
- National Heart & Lung Institute, Imperial College London, London, W12 0NN, UK.
| | - Tom Cull
- Unilever, Colworth Science Park, Sharnbrook, Bedford, MK44 1LQ, UK.
| | - George P Daston
- Mason Business Center, The Procter & Gamble Company, Cincinnati, OH, 45040, USA.
| | - Lorna Ewart
- Veroli Consulting Limited, Cambridge, UK; Emulate Inc, 27 Dry Dock Avenue, Boston, MA, 02210, USA.
| | - Thomas B Knudsen
- U.S. Environmental Protection Agency, Office of Research and Development, Center for Computational Toxicology and Exposure, Research Triangle Park, NC, 27711, USA.
| | - Irene Manou
- European Partnership for Alternative Approaches to Animal Testing (EPAA) Industry Secretariat, Belgium.
| | - Sebastian Maurer-Stroh
- Innovations in Chemical and Food Safety, Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street #07-01 Matrix, Singapore, 138671, Singapore; Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore, 117543, Singapore.
| | | | | | - Pär Nordlund
- Department of Oncology and Pathology, Karolinska Institutet, 17177, Stockholm, Sweden; Institute of Molecular and Cellular Biology, A*STAR, 61 Biopolis Drive, 138673, Singapore.
| | - Ruth A Roberts
- School of Chemistry, University of Birmingham, Birmingham, B15 2TT, UK.
| | - Thomas Steger-Hartmann
- Investigational Toxicology, Bayer AG, Pharmaceuticals, Müllerstraβe 178, 13353, Berlin, Germany.
| | | | - Mark R Viant
- School of Biosciences, University of Birmingham, Birmingham, B15 2TT, UK.
| | - Mathieu Vinken
- Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.
| | - Maurice Whelan
- European Commission, Joint Research Centre (JRC), Italy.
| | - Zvonar Zvonimir
- European Partnership for Alternative Approaches to Animal Testing (EPAA) Industry Secretariat, Belgium.
| | - Mark T D Cronin
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK.
| |
Collapse
|
45
|
Rogiers V, Benfenati E, Bernauer U, Bodin L, Carmichael P, Chaudhry Q, Coenraads PJ, Cronin MT, Dent M, Dusinska M, Ellison C, Ezendam J, Gaffet E, Galli CL, Goebel C, Granum B, Hollnagel HM, Kern PS, Kosemund-Meynen K, Ouédraogo G, Panteri E, Rousselle C, Stepnik M, Vanhaecke T, von Goetz N, Worth A. The way forward for assessing the human health safety of cosmetics in the EU - Workshop proceedings. Toxicology 2020; 436:152421. [DOI: 10.1016/j.tox.2020.152421] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 02/21/2020] [Accepted: 02/25/2020] [Indexed: 12/20/2022]
|
46
|
Moxon TE, Li H, Lee MY, Piechota P, Nicol B, Pickles J, Pendlington R, Sorrell I, Baltazar MT. Application of physiologically based kinetic (PBK) modelling in the next generation risk assessment of dermally applied consumer products. Toxicol In Vitro 2020; 63:104746. [DOI: 10.1016/j.tiv.2019.104746] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Revised: 12/04/2019] [Accepted: 12/09/2019] [Indexed: 02/06/2023]
|
47
|
Nymark P, Bakker M, Dekkers S, Franken R, Fransman W, García-Bilbao A, Greco D, Gulumian M, Hadrup N, Halappanavar S, Hongisto V, Hougaard KS, Jensen KA, Kohonen P, Koivisto AJ, Dal Maso M, Oosterwijk T, Poikkimäki M, Rodriguez-Llopis I, Stierum R, Sørli JB, Grafström R. Toward Rigorous Materials Production: New Approach Methodologies Have Extensive Potential to Improve Current Safety Assessment Practices. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2020; 16:e1904749. [PMID: 31913582 DOI: 10.1002/smll.201904749] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 12/09/2019] [Indexed: 06/10/2023]
Abstract
Advanced material development, including at the nanoscale, comprises costly and complex challenges coupled to ensuring human and environmental safety. Governmental agencies regulating safety have announced interest toward acceptance of safety data generated under the collective term New Approach Methodologies (NAMs), as such technologies/approaches offer marked potential to progress the integration of safety testing measures during innovation from idea to product launch of nanomaterials. Divided in overall eight main categories, searchable databases for grouping and read across purposes, exposure assessment and modeling, in silico modeling of physicochemical structure and hazard data, in vitro high-throughput and high-content screening assays, dose-response assessments and modeling, analyses of biological processes and toxicity pathways, kinetics and dose extrapolation, consideration of relevant exposure levels and biomarker endpoints typify such useful NAMs. Their application generally agrees with articulated stakeholder needs for improvement of safety testing procedures. They further fit for inclusion and add value in nanomaterials risk assessment tools. Overall 37 of 50 evaluated NAMs and tiered workflows applying NAMs are recommended for considering safer-by-design innovation, including guidance to the selection of specific NAMs in the eight categories. An innovation funnel enriched with safety methods is ultimately proposed under the central aim of promoting rigorous nanomaterials innovation.
Collapse
Affiliation(s)
- Penny Nymark
- Karolinska Institutet, Institute of Environmental Medicine, Nobels väg 13, 171 77, Stockholm, Sweden
- Department of Toxicology, Misvik Biology, Karjakatu 35 B, 20520, Turku, Finland
| | - Martine Bakker
- National Institute for Public Health and the Environment, RIVM, P.O. Box 1, 3720 BA, Bilthoven, The Netherlands
| | - Susan Dekkers
- National Institute for Public Health and the Environment, RIVM, P.O. Box 1, 3720 BA, Bilthoven, The Netherlands
| | - Remy Franken
- Netherlands Organisation for Applied Scientific Research, TNO, P.O. Box 96800, NL-2509 JE, The Hague, The Netherlands
| | - Wouter Fransman
- Netherlands Organisation for Applied Scientific Research, TNO, P.O. Box 96800, NL-2509 JE, The Hague, The Netherlands
| | - Amaia García-Bilbao
- GAIKER Technology Centre, Parque Tecnológico, Ed. 202, 48170, Zamudio, Bizkaia, Spain
| | - Dario Greco
- Faculty of Medicine and Health Technology, Tampere University, Korkeakoulunkatu 6, 33720, Tampere, Finland
- Institute of Biotechnology, University of Helsinki, P.O. Box 56, FI-00014, Helsinki, Finland
| | - Mary Gulumian
- National Institute for Occupational Health, 25 Hospital St, Constitution Hill, 2000, Johannesburg, South Africa
- Haematology and Molecular Medicine Department, University of the Witwatersrand, 7 York Road, Parktown, 2193, Johannesburg, South Africa
| | - Niels Hadrup
- National Research Center for the Work Environment, Lersø Parkallé 105, 2100, Copenhagen, Denmark
| | - Sabina Halappanavar
- Environmental Health Science and Research Bureau, Health Canada, 50 Colombine Driveway, Ottawa, ON, K1A 0K9, Canada
| | - Vesa Hongisto
- Department of Toxicology, Misvik Biology, Karjakatu 35 B, 20520, Turku, Finland
| | - Karin Sørig Hougaard
- National Research Center for the Work Environment, Lersø Parkallé 105, 2100, Copenhagen, Denmark
| | - Keld Alstrup Jensen
- National Research Center for the Work Environment, Lersø Parkallé 105, 2100, Copenhagen, Denmark
| | - Pekka Kohonen
- Karolinska Institutet, Institute of Environmental Medicine, Nobels väg 13, 171 77, Stockholm, Sweden
- Department of Toxicology, Misvik Biology, Karjakatu 35 B, 20520, Turku, Finland
| | - Antti Joonas Koivisto
- National Research Center for the Work Environment, Lersø Parkallé 105, 2100, Copenhagen, Denmark
| | - Miikka Dal Maso
- Aerosol Physics Laboratory, Physics Unit, Tampere University, Korkeakoulunkatu 6, 33720, Tampere, Finland
| | - Thies Oosterwijk
- Netherlands Organisation for Applied Scientific Research, TNO, P.O. Box 96800, NL-2509 JE, The Hague, The Netherlands
| | - Mikko Poikkimäki
- Aerosol Physics Laboratory, Physics Unit, Tampere University, Korkeakoulunkatu 6, 33720, Tampere, Finland
| | | | - Rob Stierum
- Netherlands Organisation for Applied Scientific Research, TNO, P.O. Box 96800, NL-2509 JE, The Hague, The Netherlands
| | - Jorid Birkelund Sørli
- National Research Center for the Work Environment, Lersø Parkallé 105, 2100, Copenhagen, Denmark
| | - Roland Grafström
- Karolinska Institutet, Institute of Environmental Medicine, Nobels väg 13, 171 77, Stockholm, Sweden
- Department of Toxicology, Misvik Biology, Karjakatu 35 B, 20520, Turku, Finland
| |
Collapse
|
48
|
Sauer UG, Barter RA, Becker RA, Benfenati E, Berggren E, Hubesch B, Hollnagel HM, Inawaka K, Keene AM, Mayer P, Plotzke K, Skoglund R, Albert O. 21 st Century Approaches for Evaluating Exposures, Biological Activity, and Risks of Complex Substances: Workshop highlights. Regul Toxicol Pharmacol 2020; 111:104583. [PMID: 31935484 DOI: 10.1016/j.yrtph.2020.104583] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 01/03/2020] [Accepted: 01/10/2020] [Indexed: 10/25/2022]
Abstract
The June 2019 workshop 21st Century Approaches for Evaluating Exposures, Biological Activity, and Risks of Complex Substances, co-organised by the International Council of Chemical Association's Long-Range Research Initiative and the European Commission's Joint Research Centre, is summarised. Focus was the need for improved approaches to evaluate the safety of complex substances. Approximately 10% and 20% of substances registered under the EU chemicals legislation are 'multi-constituent substances' and 'substances of unknown or variable compositions, complex reaction products and biological substances' (UVCBs), respectively, and UVCBs comprise approximately 25% of the U.S. Toxic Substances Control Act Inventory. Workshop participants were asked to consider how the full promise of new approach methodologies (NAMs) could be brought to bear to evaluate complex substances. Sessions focused on using NAMs for screening, biological profiling, and in complex risk evaluations; improving read-across approaches employing new data streams; and methods to evaluate exposure and dosimetry. The workshop concluded with facilitated discussions to explore actionable steps forward. Given the diversity of complex substances, no single 'correct' approach was seen as workable. The path forward should focus on 'learning by doing' by developing and openly sharing NAM-based fit-for-purpose case examples for evaluating biological activity, exposures and risks of complex substances.
Collapse
Affiliation(s)
- Ursula G Sauer
- Scientific Consultancy - Animal Welfare, Neubiberg, Germany.
| | | | | | - Emilio Benfenati
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | | | - Bruno Hubesch
- European Chemical Industry Council (Cefic), Brussels, Belgium; Hubesch Consult BVBA, Sint-Pieters-Leeuw, Belgium
| | | | | | | | - Philipp Mayer
- Technical University of Denmark, Kongens Lyngby, Denmark
| | | | | | - Océane Albert
- European Chemical Industry Council (Cefic), Brussels, Belgium
| |
Collapse
|
49
|
Krewski D, Andersen ME, Tyshenko MG, Krishnan K, Hartung T, Boekelheide K, Wambaugh JF, Jones D, Whelan M, Thomas R, Yauk C, Barton-Maclaren T, Cote I. Toxicity testing in the 21st century: progress in the past decade and future perspectives. Arch Toxicol 2019; 94:1-58. [DOI: 10.1007/s00204-019-02613-4] [Citation(s) in RCA: 124] [Impact Index Per Article: 24.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Accepted: 11/05/2019] [Indexed: 12/19/2022]
|
50
|
Finding synergies for the 3Rs – Repeated Dose Toxicity testing: Report from an EPAA Partners' Forum. Regul Toxicol Pharmacol 2019; 108:104470. [DOI: 10.1016/j.yrtph.2019.104470] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 07/30/2019] [Accepted: 08/30/2019] [Indexed: 11/21/2022]
|